<?xml version="1.0" encoding="UTF-8"?>
<PAPER>

<BODY>
<DIV><P>
</P>
<P>[0001] Title: Controlled-Release Oral Dosage Form
FIELD OF THE INVENTION
The present invention relates to an oral dosage form. In particular, the invention relates to controlled-release oral dosage which is suitable for various drugs.
BACKGROUND OF THE INVENTION
In the field of controlled-release drugs several solutions have been proposed in the last decade. However, there is still some room for improvement with respect to the delivery of various drugs, such as for drugs having a pH-dependent solubility. Many drugs have very different solubilities depending on the pH of the environment into which they are. As a consequence, these drugs will have dissolution rates, and therefore release rates from release devices, which will be different in stomach than in intestine, unless the release device is designed to compensate for the variability in release rate with pH.
A second difficulty in developing a once-a-day dosage form for a pH-dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.99" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is that some molecules have in addition a short absorption window, being mainly absorbed from the upper part of the small intestine, as indicated in US Patent No. 5,262,173 for <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.390" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne>, for example. In order to obtain a satisfactory once-a-day product, it is highly desirable to extend the residence time of the dosage form in the gastrointestinal region where absorption is optimal.
One of the previously proposed ways to extend retention of a <ne type="ONT" id="WO2007038867.HC.class-names.100" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> delivery device in the upper gastro- intestinal region was to retain it in the stomach. This can be achieved by the use of a large diameter floating device, ingested along with the main meal of the day (Hou et al. Critical Reviews(TM) in Therapeutic <ne type="ONT" id="WO2007038867.HC.class-names.101" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">Drug</ne> Carrier Systems, 20(6), 461-497, 2003). A large floating tablet is retained in the stomach after a meal till after the content of the stomach is emptied to the intestine at the end of the digestive cycle. Using this approach, the transit time in stomach and small intestine can be extended up to 6 to 10 hours. As previously indicated, a major difficulty encountered in <ne type="ONT" id="WO2007038867.HC.class-names.102" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> delivery is the variation of the solubility of a <ne type="ONT" id="WO2007038867.HC.class-names.103" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> as a function of pH. The difficulty of developing a controlled-release dosage form with molecules having a pH-dependant solubility has been the subject of many publications. Some authors have used high molecular weight <ne id="WO2007038867.HC.class-names.20" epochem-id="EPOCHEM:NEW:CLASS:501" name="polyacids" comment="" chebi-id="WO2007038867:868264" relevant="false" type="CLASS">polyacids</ne> to offset the reduced solubility of the <ne type="ONT" id="WO2007038867.HC.class-names.104" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> as pH increases. The <ne id="WO2007038867.HC.class-names.21" epochem-id="EPOCHEM:NEW:CLASS:501" name="polyacids" comment="" chebi-id="WO2007038867:868264" relevant="false" type="CLASS">polyacids</ne> become soluble at higher pH, which triggers erosion of the system. The rapid erosion of the system counter-balances the decreased solubility of the <ne type="ONT" id="WO2007038867.HC.class-names.105" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>.
WO 97/18814 describes a formulation comprising a low molecular weight polyethylene oxide, <ne type="CHEMICAL" id="WO2007038867.HC.substance-names.4" epochem-id="EPOCHEM:NEW:SUBSTANCE:304" name="HPMC" comment="" chebi-id="WO2007038867:625050" relevant="false">HPMC</ne> and one or more enteric polymers such as <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.209" epochem-id="EPOCHEM:COMPOUND:734" name="methacrylic acid" comment="" chebi-id="CHEBI:25219" relevant="false">methacrylic acid</ne> copolymers. With compounds being more soluble at low pH value, the <ne type="ONT" id="WO2007038867.HC.class-names.106" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> release from the tablet in the stomach is reduced by the <ne id="WO2007038867.HC.class-names.23" epochem-id="EPOCHEM:NEW:CLASS:503" name="enteric polymer" comment="" chebi-id="WO2007038867:153351" relevant="false" type="CLASS">enteric polymer</ne>. However, as the device travel along the gastrointestinal tract and the pH increases, the erosion rate increases to compensate for the reduced compound solubility.
U.S. Patent No. 4,968,508 describes a formulation comprising a <ne id="WO2007038867.HC.class-names.22" epochem-id="EPOCHEM:NEW:CLASS:502" name="hydrophilic polymer" comment="" chebi-id="WO2007038867:735823" relevant="false" type="CLASS">hydrophilic polymer</ne> (e.g. <ne type="CHEMICAL" id="WO2007038867.HC.substance-names.5" epochem-id="EPOCHEM:NEW:SUBSTANCE:304" name="HPMC" comment="" chebi-id="WO2007038867:625050" relevant="false">HPMC</ne>) and an <ne id="WO2007038867.HC.class-names.24" epochem-id="EPOCHEM:NEW:CLASS:503" name="enteric polymer" comment="" chebi-id="WO2007038867:153351" relevant="false" type="CLASS">enteric polymer</ne> (e.g. Eudragit L-100- 55). In acidic medium, the <ne id="WO2007038867.HC.class-names.25" epochem-id="EPOCHEM:NEW:CLASS:503" name="enteric polymer" comment="" chebi-id="WO2007038867:153351" relevant="false" type="CLASS">enteric polymer</ne> is insoluble and acts as a part of the matrix and thus contributes to the retardation of the <ne type="ONT" id="WO2007038867.HC.class-names.107" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> release. At higher pH-values, the <ne id="WO2007038867.HC.class-names.26" epochem-id="EPOCHEM:NEW:CLASS:503" name="enteric polymer" comment="" chebi-id="WO2007038867:153351" relevant="false" type="CLASS">enteric polymer</ne> dissolves and thus increases the permeability of the dosage form.
U.S. Patent No. 4,792,452 describes a formulation containing an anionic (<ne type="CHEMICAL" id="WO2007038867.HC.substance-names.1" epochem-id="EPOCHEM:NEW:SUBSTANCE:88" name="sodiumalginate" comment="" chebi-id="WO2007038867:220205" relevant="false">sodium alginate</ne>) and non-ionic polymer (<ne type="CHEMICAL" id="WO2007038867.HC.substance-names.6" epochem-id="EPOCHEM:NEW:SUBSTANCE:304" name="HPMC" comment="" chebi-id="WO2007038867:625050" relevant="false">HPMC</ne>). At low pH values, <ne type="CHEMICAL" id="WO2007038867.HC.substance-names.2" epochem-id="EPOCHEM:NEW:SUBSTANCE:88" name="sodiumalginate" comment="" chebi-id="WO2007038867:220205" relevant="false">sodium alginate</ne> precipitates in the hydrated gel layer as <ne type="CHEMICAL" id="WO2007038867.HC.substance-names.3" epochem-id="EPOCHEM:NEW:SUBSTANCE:39" name="alginic acid" comment="" chebi-id="WO2007038867:325420" relevant="false">alginic acid</ne> and provides resistance against erosion,. At higher pH-values, the alginate forms a soluble salt, thus providing less resistance to erosion. The release mechanism changes from predominantly diffusion-controlled to predominantly erosion-controlled. The resulting higher permeability of the gel layer at high pH-value compensates the lower <ne type="ONT" id="WO2007038867.HC.class-names.108" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> solubility, leading to a constant <ne type="ONT" id="WO2007038867.HC.class-names.109" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> release rates at different pH-values. The approaches described above would be well suited to release <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.391" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> independently of surrounding's pH, but would fail to extend the residence time of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.392" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> in the gastro-intestinal region.
In other cases low molecular weight acids in "reservoir" systems have been used. The matrix tablet or film coated device acts as a reservoir where the <ne type="ONT" id="WO2007038867.HC.class-names.33" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> keeps internal pH low, even when the device is in high pH medium.
Kranz et al. in Pharmaceutical Sciences "Development of a single unit extended release formulation for ZK 811 752, a weakly basic <ne type="ONT" id="WO2007038867.HC.class-names.110" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>" (2005, article in press) describes the use of <ne type="ONT" id="WO2007038867.HC.class-names.27" epochem-id="EPOCHEM:NEW:CLASS:370" name="organic acids" comment="" chebi-id="WO2007038867:387662" relevant="false">organic acids</ne> such as <ne type="LIGAND" id="WO2007038867.HC.ligand-names.1" epochem-id="EPOCHEM:NEW:LIGAND:161" name="fumaric" comment="" chebi-id="WO2007038867:130295" relevant="true">fumaric</ne>, <ne type="LIGAND" id="WO2007038867.HC.ligand-names.3" epochem-id="EPOCHEM:NEW:LIGAND:81" name="tartaric" comment="" chebi-id="WO2007038867:310981" relevant="false">tartaric</ne>, <ne type="LIGAND" id="WO2007038867.HC.ligand-names.6" epochem-id="EPOCHEM:NEW:LIGAND:162" name="adipic" comment="" chebi-id="WO2007038867:898634" relevant="false">adipic</ne>, <ne type="LIGAND" id="WO2007038867.HC.ligand-names.7" epochem-id="EPOCHEM:NEW:LIGAND:163" name="glutamic" comment="" chebi-id="WO2007038867:665033" relevant="false">glutamic</ne> and <ne type="LIGAND" id="WO2007038867.HC.ligand-names.8" epochem-id="EPOCHEM:NEW:LIGAND:164" name="sorbic" comment="" chebi-id="WO2007038867:32944" relevant="false">sorbic</ne> in combination with matrix former polymers like Kollidon SR, <ne type="CHEMICAL" id="WO2007038867.HC.substance-names.12" epochem-id="EPOCHEM:NEW:SUBSTANCE:98" name="ethylcellulose" comment="" chebi-id="WO2007038867:703243" relevant="false">ethylcellulose</ne>, or <ne type="CHEMICAL" id="WO2007038867.HC.substance-names.7" epochem-id="EPOCHEM:NEW:SUBSTANCE:304" name="HPMC" comment="" chebi-id="WO2007038867:625050" relevant="false">HPMC</ne>. The addition of <ne type="ONT" id="WO2007038867.HC.class-names.28" epochem-id="EPOCHEM:NEW:CLASS:370" name="organic acids" comment="" chebi-id="WO2007038867:387662" relevant="false">organic acids</ne> to all three matrix formers was found to maintain low pH-values within the tablets in <ne id="WO2007038867.HC.class-names.96" epochem-id="EPOCHEM:NEW:CLASS:1017" name="phosphate" comment="" chebi-id="WO2007038867:367291" relevant="false" type="CLASS">phosphate</ne> buffer pH 6.8. Streubel et al. in Journal of Controlled Release, 67 (2000) 101-
</P>
<P>110, describe a pH-independent release of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.339" epochem-id="EPOCHEM:NEW:COMPOUND:1982" name="verapamil HCI" comment="verapamil HCl" chebi-id="WO2007038867:202031" relevant="false">verapamil HCI</ne> from matrix tablets consisting of <ne type="CHEMICAL" id="WO2007038867.HC.substance-names.13" epochem-id="EPOCHEM:NEW:SUBSTANCE:98" name="ethylcellulose" comment="" chebi-id="WO2007038867:703243" relevant="false">ethylcellulose</ne> or <ne type="CHEMICAL" id="WO2007038867.HC.substance-names.8" epochem-id="EPOCHEM:NEW:SUBSTANCE:304" name="HPMC" comment="" chebi-id="WO2007038867:625050" relevant="false">HPMC</ne> by the addition of <ne type="LIGAND" id="WO2007038867.HC.ligand-names.2" epochem-id="EPOCHEM:NEW:LIGAND:161" name="fumaric" comment="" chebi-id="WO2007038867:130295" relevant="true">fumaric</ne>, <ne type="LIGAND" id="WO2007038867.HC.ligand-names.9" epochem-id="EPOCHEM:NEW:LIGAND:164" name="sorbic" comment="" chebi-id="WO2007038867:32944" relevant="false">sorbic</ne> or <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.227" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>. They demonstrated that the addition of <ne type="ONT" id="WO2007038867.HC.class-names.29" epochem-id="EPOCHEM:NEW:CLASS:370" name="organic acids" comment="" chebi-id="WO2007038867:387662" relevant="false">organic acids</ne> to both matrix formers maintained low pH-values within the tablets during <ne type="ONT" id="WO2007038867.HC.class-names.111" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> release in <ne id="WO2007038867.HC.class-names.97" epochem-id="EPOCHEM:NEW:CLASS:1017" name="phosphate" comment="" chebi-id="WO2007038867:367291" relevant="false" type="CLASS">phosphate</ne> buffer pH 6.8.
Gabr in Eur. J. Pharm. Biopharm, 38(6) (1992) 199-202 studied the effect of <ne type="LIGAND" id="WO2007038867.HC.ligand-names.12" epochem-id="EPOCHEM:NEW:LIGAND:78" name="citric" comment="" chebi-id="WO2007038867:610027" relevant="false">citric</ne>, <ne type="LIGAND" id="WO2007038867.HC.ligand-names.4" epochem-id="EPOCHEM:NEW:LIGAND:81" name="tartaric" comment="" chebi-id="WO2007038867:310981" relevant="false">tartaric</ne>, and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.275" epochem-id="EPOCHEM:COMPOUND:381" name="succinic acid" comment="" chebi-id="CHEBI:15741" relevant="false">succinic acid</ne> on the <ne type="ONT" id="WO2007038867.HC.class-names.112" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> release from matrix tablets consisting of cellulose acetate and beeswax as matrix former in various ratio. The "reservoir" systems described above present several drawbacks. One of them is the particular shape of the release profile obtained from reservoir systems: the release rate decreases progressively leading to a first order release profile, often described as an exponential decay. The desired release profile for <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.393" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> or other molecules cannot always be met by such systems. Moreover, for <ne type="ONT" id="WO2007038867.HC.class-names.113" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> with short absorption windows, the likelihood of lower bioavailability is high as the last 25% of the <ne type="ONT" id="WO2007038867.HC.class-names.114" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is released very slowly. Finally, such systems but would fail to extend the residence time of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.394" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> in the gastro-intestinal region.
It would therefore be highly desirable to be provided with a controlled-release dosage form that permit to overcome the prior art drawbacks.
SUMMARY OF THE INVENTION
In accordance with one aspect of the present invention, there is provided a controlled-release oral dosage form suitable for administration to a mammal. The dosage form comprises :
a <ne type="ONT" id="WO2007038867.HC.class-names.115" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.1" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof, wherein the dosage form releases no more than 60 % of the total amount of the <ne type="ONT" id="WO2007038867.HC.class-names.116" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> within about a first hour, the remaining amount of the <ne type="ONT" id="WO2007038867.HC.class-names.117" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> being released over a period of time of about 5 to about 8 hours subsequent to the first hour.
In accordance with another aspect of the present invention there is provided a controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.118" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.2" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof,
wherein the <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.3" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> reduces the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.119" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 1.0 to about 3.5, and enhances the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.120" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 4.0 to about 7.0.
In accordance with another aspect of the present invention there is provided a controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.121" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.34" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or a salt thereof, the <ne type="ONT" id="WO2007038867.HC.class-names.35" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> having a solubility lower than 20 mg/mL (preferably lower than 10 mg/mL, and more preferably lower than 3.0 mg/mL) at a pH below 5.0 and a solubility of at least 100 mg/mL (preferably at least 200 mg/mL and more preferably at least
</P>
<P>300 mg/mL) at a pH higher than 5.0, wherein the <ne type="ONT" id="WO2007038867.HC.class-names.36" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or salt thereof is effective for reducing the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.122" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 1.0 to about 3.5, and enhancing the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.123" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 4.0 to about 7.0. In accordance with another aspect of the present invention there is provided a controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.124" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.37" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or a salt thereof, the <ne type="ONT" id="WO2007038867.HC.class-names.38" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> having a solubility lower than 20 mg/mL (preferably lower than 10 mg/mL, and more preferably lower than 3.0 mg/mL) at a pH below 5.0 and a solubility of at least 100 mg/mL (preferably at least 200 mg/mL and more preferably at least 300 mg/mL) at a pH higher than 5.0,
wherein the <ne type="ONT" id="WO2007038867.HC.class-names.39" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or salt thereof is effective for maintaining the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.125" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 5 % by weight per hour to about 50 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.126" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when the dosage form is at a pH of about 4.0 to about 7.0.
In accordance with another aspect of the present invention there is provided a controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.127" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.40" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or a salt thereof, the <ne type="ONT" id="WO2007038867.HC.class-names.41" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> having a solubility lower than 20 mg/mL (preferably lower than 10 mg/mL, and more preferably lower than 3.0 mg/mL) at a pH below 5.0 and a solubility of at least 100 mg/mL (preferably at least 200 mg/mL and more preferably at least
</P>
<P>300 mg/mL) at a pH higher than 5.0,
wherein the <ne type="ONT" id="WO2007038867.HC.class-names.42" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or salt thereof is effective for maintaining the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.128" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 10 % by weight per hour to about 60 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.129" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when the dosage form is at a pH of about
</P>
<P>1.0 to about 3.5. In accordance with another aspect of the present invention there is provided a controlled-release oral dosage form suitable for human administration comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.130" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.43" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or a salt thereof, the <ne type="ONT" id="WO2007038867.HC.class-names.44" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> having a solubility lower than 20 mg/mL (preferably lower than 10 mg/mL, and more preferably lower than 3.0 mg/mL) at a pH below 5.0 and a solubility of at least 100 mg/mL (preferably at least 200 mg/mL and more preferably at least
</P>
<P>300 mg/mL) at a pH higher than 5.0,
wherein the dosage form releases no more than 60 % of the total amount of the <ne type="ONT" id="WO2007038867.HC.class-names.131" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> within a first hour, the remaining amount of the <ne type="ONT" id="WO2007038867.HC.class-names.132" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> being released over a period of time of about 5 to about 8 hours subsequent to the first hour.
In accordance with another aspect of the present invention there is provided a controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.133" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.45" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.212" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.228" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.243" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.4" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.258" epochem-id="EPOCHEM:COMPOUND:811" name="benzoic acid" comment="" chebi-id="CHEBI:30746" relevant="false">benzoic acid</ne> and salts thereof,
wherein the <ne type="ONT" id="WO2007038867.HC.class-names.46" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or salt thereof is effective for maintaining the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.134" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 5 % by weight per hour to about 50 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.135" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when the dosage form is at a pH of about
</P>
<P>4.0 to about 7.0.
In accordance with another aspect of the present invention there is provided a controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.136" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.47" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.213" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.229" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.244" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.5" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.259" epochem-id="EPOCHEM:COMPOUND:811" name="benzoic acid" comment="" chebi-id="CHEBI:30746" relevant="false">benzoic acid</ne> and salts thereof, wherein the <ne type="ONT" id="WO2007038867.HC.class-names.48" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or salt thereof is effective for maintaining the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.137" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 10 % by weight per hour to about 60 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.138" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when the dosage form is at a pH of about 1.0 to about 3.5.
In accordance with another aspect of the present invention there is provided controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.139" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, and an <ne type="ONT" id="WO2007038867.HC.class-names.49" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.214" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.230" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.245" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.6" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.260" epochem-id="EPOCHEM:COMPOUND:811" name="benzoic acid" comment="" chebi-id="CHEBI:30746" relevant="false">benzoic acid</ne> and salts thereof,
wherein the dosage form releases no more than 60 % of the total amount of the <ne type="ONT" id="WO2007038867.HC.class-names.140" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> within a first hour, the remaining amount of the <ne type="ONT" id="WO2007038867.HC.class-names.141" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> being released over a period of time of about 5 to about 8 hours subsequent to the first hour. In accordance with another aspect of the present invention there is provided a controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.142" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.50" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.215" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.231" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne> <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.246" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.7" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, and salts thereof
wherein the <ne type="ONT" id="WO2007038867.HC.class-names.51" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or salt thereof reduces the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.143" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 1.0 to about 3.5, and enhances the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.144" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 4.0 to about 7.0. In accordance with another aspect of the present invention there is provided a controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.145" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.52" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.216" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.232" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.247" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.8" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.261" epochem-id="EPOCHEM:COMPOUND:811" name="benzoic acid" comment="" chebi-id="CHEBI:30746" relevant="false">benzoic acid</ne> and salts thereof
wherein the <ne type="ONT" id="WO2007038867.HC.class-names.146" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in the dosage form has a dissolution rate of about 10% by weight per hour to about 60% by weight per hour when being at a pH of about 1.0 to about 3.5, and a dissolution rate of about 5% by weight per hour to about 50% by weight per hour when being at a pH of about 4.0 to about 7.0.
In accordance with another aspect of the present invention there is provided a controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.147" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.53" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.217" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.233" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.248" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.9" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.262" epochem-id="EPOCHEM:COMPOUND:811" name="benzoic acid" comment="" chebi-id="CHEBI:30746" relevant="false">benzoic acid</ne> and salts thereof
wherein the <ne type="ONT" id="WO2007038867.HC.class-names.148" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in the dosage form has a dissolution rate which is substantially the same when submitted to a pH of about 1.0 to about 3.5 and when submitted to a pH of about 4.0 to about 7.0.
It was found that the dosage forms of the present invention were very efficient for the <ne type="ONT" id="WO2007038867.HC.class-names.149" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> delivery of pH-dependent solubility drugs. It was also found that such dosage forms were particularly useful for drugs having a high solubility at pH of about 1.0 to about 3.5 (pH of stomach) and a lower solubility at pH of about 4.0 to about 7.0 (pH of intestine). In fact, the <ne type="ONT" id="WO2007038867.HC.class-names.30" epochem-id="EPOCHEM:NEW:CLASS:370" name="organic acids" comment="" chebi-id="WO2007038867:387662" relevant="false">organic acids</ne> present in these dosage forms permitted to reduce the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.150" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at pH of about 1.0 to about 3.5, and to enhance the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.151" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 4.0 to about 7.0. For the purpose of the present invention the following terms are defined below.
The expression "pH-dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.152" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>" as used herein refers to a <ne type="ONT" id="WO2007038867.HC.class-names.153" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> which has a dissolution rate that will vary in accordance with pH. In fact, such a <ne type="ONT" id="WO2007038867.HC.class-names.154" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> will have as example a solubility which will be different at pH of 1.0 to 3.5 (pH of stomach) than at pH 4.0 to 7.0 (pH of intestine).
The expression "pH insensitive" as uses herein refers to a condition so that when comparing the percent released under various pH conditions, the percent released for any given time point does not vary by more than 30% preferably less than 20%, most preferably less than 15%. In the dosage forms of the present invention the <ne type="ONT" id="WO2007038867.HC.class-names.155" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is preferably a pH-dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.156" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>. Preferably, such a <ne type="ONT" id="WO2007038867.HC.class-names.157" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is substantially soluble at a first pH of about 1.0 to about 3.5 and substantially less soluble at a pH of about 4.0 to 7.0 than at the first pH. The <ne type="ONT" id="WO2007038867.HC.class-names.158" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> can be selected from the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.83" epochem-id="EPOCHEM:NEW:COMPOUND:1017" name="doxycycline" comment="" chebi-id="WO2007038867:253304" relevant="false">doxycycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.88" epochem-id="EPOCHEM:COMPOUND:5332" name="tetracycline" comment="" chebi-id="CHEBI:27902" relevant="false">tetracycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.91" epochem-id="EPOCHEM:NEW:COMPOUND:1018" name="oxytetracycline" comment="" chebi-id="WO2007038867:762180" relevant="false">oxytetracycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.395" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.140" epochem-id="EPOCHEM:NEW:COMPOUND:1020" name="chlortetracycline" comment="" chebi-id="WO2007038867:557980" relevant="false">chlortetracycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.166" epochem-id="EPOCHEM:NEW:COMPOUND:1025" name="trimebutine" comment="" chebi-id="WO2007038867:857445" relevant="false">trimebutine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.158" epochem-id="EPOCHEM:NEW:COMPOUND:1022" name="demeclocycline" comment="" chebi-id="WO2007038867:666197" relevant="false">demeclocycline</ne> and salts thereof. Preferably, the <ne type="ONT" id="WO2007038867.HC.class-names.159" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.298" epochem-id="EPOCHEM:NEW:COMPOUND:1023" name="minocycline hydrochloride" comment="" chebi-id="WO2007038867:965127" relevant="false">minocycline hydrochloride</ne> or <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.167" epochem-id="EPOCHEM:NEW:COMPOUND:1025" name="trimebutine" comment="" chebi-id="WO2007038867:857445" relevant="false">trimebutine</ne>.
In the dosage forms of the present invention, the <ne type="ONT" id="WO2007038867.HC.class-names.160" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> can alternatively selected from the group consisting of <ne type="ONT" id="WO2007038867.HC.class-names.2" epochem-id="EPOCHEM:NEW:CLASS:235" name="adrenergic agents" comment="" chebi-id="CHEBI:37962" relevant="false">adrenergic agents</ne> such as salts of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.277" epochem-id="EPOCHEM:NEW:COMPOUND:1035" name="ephedrine" comment="" chebi-id="CHEBI:15407" relevant="false">ephedrine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.278" epochem-id="EPOCHEM:NEW:COMPOUND:1036" name="desoxyephedrine" comment="" chebi-id="WO2007038867:930419" relevant="false">desoxyephedrine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.279" epochem-id="EPOCHEM:COMPOUND:4098" name="phenylephrine" comment="" chebi-id="CHEBI:8093" relevant="false">phenylephrine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.280" epochem-id="EPOCHEM:NEW:COMPOUND:1037" name="epinephrine" comment="" chebi-id="CHEBI:28918" relevant="false">epinephrine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.281" epochem-id="EPOCHEM:NEW:COMPOUND:1038" name="salbutamol" comment="" chebi-id="CHEBI:2549" relevant="false">salbutamol</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.282" epochem-id="EPOCHEM:NEW:COMPOUND:1039" name="terbutaline" comment="" chebi-id="CHEBI:9449" relevant="false">terbutaline</ne> and the like; <ne type="ONT" id="WO2007038867.HC.class-names.3" epochem-id="EPOCHEM:NEW:CLASS:236" name="cholinergic agents" comment="" chebi-id="WO2007038867:874371" relevant="false">cholinergic agents</ne> such as salts of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.283" epochem-id="EPOCHEM:NEW:COMPOUND:1040" name="physostigmine" comment="" chebi-id="CHEBI:27953" relevant="false">physostigmine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.284" epochem-id="EPOCHEM:NEW:COMPOUND:1041" name="neostigmine" comment="" chebi-id="CHEBI:7514" relevant="false">neostigmine</ne> and the like; <ne type="ONT" id="WO2007038867.HC.class-names.4" epochem-id="EPOCHEM:NEW:CLASS:237" name="curariform agents" comment="" chebi-id="WO2007038867:74904" relevant="false">curariform agents</ne> such as salts of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.285" epochem-id="EPOCHEM:NEW:COMPOUND:1042" name="chlorisondamine" comment="" chebi-id="WO2007038867:981676" relevant="false">chlorisondamine</ne> and the like; <ne type="ONT" id="WO2007038867.HC.class-names.5" epochem-id="EPOCHEM:NEW:CLASS:238" name="antidepressants" comment="" chebi-id="CHEBI:35469" relevant="false">antidepressants</ne> like salts of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.286" epochem-id="EPOCHEM:COMPOUND:4233" name="amitriptyline" comment="" chebi-id="CHEBI:2666" relevant="false">amitriptyline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.287" epochem-id="EPOCHEM:NEW:COMPOUND:1043" name="nortriptyline" comment="" chebi-id="CHEBI:7640" relevant="false">nortriptyline</ne>, and the like; and <ne id="WO2007038867.HC.class-names.6" epochem-id="EPOCHEM:NEW:CLASS:239" name="cardioactive agents" comment="" chebi-id="WO2007038867:219841" relevant="false" type="CLASS">cardioactive agents</ne> such as <ne id="WO2007038867.HC.class-names.98" epochem-id="EPOCHEM:NEW:CLASS:1177" name="salts of verapamil" comment="" chebi-id="WO2007038867:388189" relevant="false" type="CLASS">salts of verapamil</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.276" epochem-id="EPOCHEM:NEW:COMPOUND:1034" name="diltiazem" comment="" chebi-id="WO2007038867:408905" relevant="false">diltiazem</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.288" epochem-id="EPOCHEM:NEW:COMPOUND:1044" name="gallapomil" comment="" chebi-id="WO2007038867:958584" relevant="false">gallapomil</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.289" epochem-id="EPOCHEM:NEW:COMPOUND:1045" name="cinnarizine" comment="" chebi-id="WO2007038867:366452" relevant="false">cinnarizine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.290" epochem-id="EPOCHEM:NEW:COMPOUND:1046" name="propranolol" comment="" chebi-id="CHEBI:8499" relevant="false">propranolol</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.292" epochem-id="EPOCHEM:COMPOUND:4118" name="metoprolol" comment="" chebi-id="CHEBI:6904" relevant="false">metoprolol</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.294" epochem-id="EPOCHEM:COMPOUND:5654" name="nadolol" comment="" chebi-id="CHEBI:7444" relevant="false">nadolol</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.295" epochem-id="EPOCHEM:NEW:COMPOUND:1047" name="clonidine" comment="" chebi-id="CHEBI:46631" relevant="false">clonidine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.296" epochem-id="EPOCHEM:NEW:COMPOUND:1048" name="methyldopa" comment="" chebi-id="WO2007038867:404571" relevant="false">methyldopa</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.297" epochem-id="EPOCHEM:COMPOUND:7925" name="nifedipine" comment="" chebi-id="CHEBI:7565" relevant="false">nifedipine</ne> or salts thereof.
The <ne type="ONT" id="WO2007038867.HC.class-names.161" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> can also be selected from the group consisting of <ne type="ONT" id="WO2007038867.HC.class-names.7" epochem-id="EPOCHEM:NEW:CLASS:240" name="antimalarials" comment="" chebi-id="CHEBI:38068" relevant="true">antimalarials</ne> such as <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.299" epochem-id="EPOCHEM:COMPOUND:6338" name="chloroquine" comment="" chebi-id="CHEBI:3638" relevant="false">chloroquine</ne> and the like; <ne type="ONT" id="WO2007038867.HC.class-names.8" epochem-id="EPOCHEM:NEW:CLASS:241" name="analgesics" comment="" chebi-id="WO2007038867:1365" relevant="false">analgesics</ne> such as <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.300" epochem-id="EPOCHEM:NEW:COMPOUND:1049" name="propoxyphene" comment="" chebi-id="WO2007038867:271124" relevant="false">propoxyphene</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.301" epochem-id="EPOCHEM:NEW:COMPOUND:1050" name="meperidine" comment="" chebi-id="WO2007038867:385969" relevant="false">meperidine</ne> and the like; <ne type="ONT" id="WO2007038867.HC.class-names.9" epochem-id="EPOCHEM:NEW:CLASS:242" name="beta-blockers" comment="" chebi-id="WO2007038867:623770" relevant="false">beta-blockers</ne> such as <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.291" epochem-id="EPOCHEM:NEW:COMPOUND:1046" name="propranolol" comment="" chebi-id="CHEBI:8499" relevant="false">propranolol</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.293" epochem-id="EPOCHEM:COMPOUND:4118" name="metoprolol" comment="" chebi-id="CHEBI:6904" relevant="false">metoprolol</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.302" epochem-id="EPOCHEM:NEW:COMPOUND:1051" name="atenolol" comment="" chebi-id="WO2007038867:275941" relevant="false">atenolol</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.303" epochem-id="EPOCHEM:NEW:COMPOUND:1052" name="labetolol" comment="" chebi-id="WO2007038867:567250" relevant="false">labetolol</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.304" epochem-id="EPOCHEM:COMPOUND:5867" name="timolol" comment="" chebi-id="CHEBI:39465" relevant="false">timolol</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.305" epochem-id="EPOCHEM:NEW:COMPOUND:1053" name="pindolol" comment="" chebi-id="CHEBI:8214" relevant="false">pindolol</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.10" epochem-id="EPOCHEM:NEW:CLASS:243" name="antimicrobial agents" comment="" chebi-id="WO2007038867:979416" relevant="false">antimicrobial agents</ne> such as <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.306" epochem-id="EPOCHEM:NEW:COMPOUND:1054" name="cephalexin" comment="" chebi-id="WO2007038867:576622" relevant="false">cephalexin</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.307" epochem-id="EPOCHEM:NEW:COMPOUND:1055" name="cefaclor" comment="" chebi-id="WO2007038867:479968" relevant="false">cefaclor</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.308" epochem-id="EPOCHEM:NEW:COMPOUND:1056" name="cefadroxil" comment="" chebi-id="WO2007038867:424887" relevant="false">cefadroxil</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.309" epochem-id="EPOCHEM:NEW:COMPOUND:1057" name="cefuroxime" comment="" chebi-id="CHEBI:3515" relevant="false">cefuroxime</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.311" epochem-id="EPOCHEM:NEW:COMPOUND:1058" name="cefuroxime axetil" comment="" chebi-id="WO2007038867:31372" relevant="false">cefuroxime axetil</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.312" epochem-id="EPOCHEM:NEW:COMPOUND:1059" name="erythromycin" comment="" chebi-id="WO2007038867:234276" relevant="false">erythromycin</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.313" epochem-id="EPOCHEM:NEW:COMPOUND:28" name="penicillin" comment="" chebi-id="CHEBI:17334" relevant="false">penicillin</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.314" epochem-id="EPOCHEM:NEW:COMPOUND:1060" name="7-[D-(aminophenylacetyl)amino]-3-chloro-8-oxo-1 - azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid" comment="" chebi-id="WO2007038867:117717" relevant="false">7-[D-(aminophenylacetyl)amino]-3-chloro-8-oxo-1 - azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid</ne>, also known as <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.315" epochem-id="EPOCHEM:NEW:COMPOUND:1061" name="loracarbef" comment="" chebi-id="WO2007038867:667215" relevant="false">loracarbef</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.316" epochem-id="EPOCHEM:NEW:COMPOUND:1062" name="7- [amino[beta]-Kmethylsulfony^aminol-phenyllacetyllaminolaminol-S-chloro-[delta]-o xo- 1-azabicyclo[4.2.0]- oct-2-ene-2-carboxylic acid" comment="7- [amino[3-[(methylsulfonyl)amino]-phenyl]acetyl]amino]amino-3-chloro-8-oxo- 1-azabicyclo[4.2.0]- oct-2-ene-2-carboxylic acid" chebi-id="WO2007038867:907284" relevant="false">7- [amino[beta]-Kmethylsulfony^aminol-phenyllacetyllaminolaminol-S-chloro-[delta]-o xo- 1-azabicyclo[4.2.0]- oct-2-ene-2-carboxylic acid</ne>, and
<ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.317" epochem-id="EPOCHEM:NEW:COMPOUND:1063" name="7-[D-amino[3-[(ethylsulfonyl) amino]phenyl]acetyl]amino-3-chloro-8-oxo-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid" comment="" chebi-id="WO2007038867:761812" relevant="false">7-[D-amino[3-[(ethylsulfonyl) amino]phenyl]acetyl]amino-3-chloro-8-oxo-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.11" epochem-id="EPOCHEM:NEW:CLASS:244" name="tranquilizers" comment="" chebi-id="WO2007038867:866738" relevant="false">tranquilizers</ne> such as <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.318" epochem-id="EPOCHEM:COMPOUND:5609" name="diazepam" comment="" chebi-id="CHEBI:4494" relevant="false">diazepam</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.319" epochem-id="EPOCHEM:COMPOUND:6379" name="chlordiazepoxide" comment="" chebi-id="CHEBI:3611" relevant="false">chlordiazepoxide</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.320" epochem-id="EPOCHEM:COMPOUND:6378" name="oxazepam" comment="" chebi-id="CHEBI:7823" relevant="false">oxazepam</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.13" epochem-id="EPOCHEM:NEW:CLASS:245" name="anticonvulsants" comment="" chebi-id="CHEBI:35623" relevant="false">anticonvulsants</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.14" epochem-id="EPOCHEM:NEW:CLASS:246" name="antihistamines" comment="" chebi-id="CHEBI:37956" relevant="false">antihistamines</ne> such as salts of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.321" epochem-id="EPOCHEM:NEW:COMPOUND:1064" name="diphenhydramine" comment="" chebi-id="WO2007038867:770838" relevant="false">diphenhydramine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.322" epochem-id="EPOCHEM:NEW:COMPOUND:1065" name="chlorpheniramine" comment="" chebi-id="WO2007038867:211964" relevant="false">chlorpheniramine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.323" epochem-id="EPOCHEM:NEW:COMPOUND:1066" name="dimenhydrinate" comment="" chebi-id="WO2007038867:992941" relevant="false">dimenhydrinate</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.324" epochem-id="EPOCHEM:NEW:COMPOUND:1067" name="tripelennamine" comment="" chebi-id="WO2007038867:471360" relevant="false">tripelennamine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.325" epochem-id="EPOCHEM:COMPOUND:6191" name="perphenazine" comment="" chebi-id="CHEBI:8028" relevant="false">perphenazine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.326" epochem-id="EPOCHEM:NEW:COMPOUND:1068" name="brompheniramine" comment="" chebi-id="WO2007038867:831081" relevant="false">brompheniramine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.327" epochem-id="EPOCHEM:NEW:COMPOUND:1069" name="chlorprophenazine" comment="" chebi-id="WO2007038867:819105" relevant="false">chlorprophenazine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.328" epochem-id="EPOCHEM:NEW:COMPOUND:1070" name="chlorprophenpyridamine" comment="" chebi-id="WO2007038867:2836" relevant="false">chlorprophenpyridamine</ne> and the like, <ne type="ONT" id="WO2007038867.HC.class-names.15" epochem-id="EPOCHEM:NEW:CLASS:247" name="antinauseants" comment="" chebi-id="WO2007038867:565236" relevant="false">antinauseants</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.16" epochem-id="EPOCHEM:NEW:CLASS:248" name="antiemetics" comment="" chebi-id="WO2007038867:475556" relevant="false">antiemetics</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.12" epochem-id="EPOCHEM:NEW:CLASS:244" name="tranquilizers" comment="" chebi-id="WO2007038867:866738" relevant="false">tranquilizers</ne> and <ne type="ONT" id="WO2007038867.HC.class-names.17" epochem-id="EPOCHEM:NEW:CLASS:249" name="muscle relaxants" comment="" chebi-id="WO2007038867:876730" relevant="false">muscle relaxants</ne> such as salts of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.329" epochem-id="EPOCHEM:NEW:COMPOUND:1071" name="fluphenazine" comment="" chebi-id="WO2007038867:747882" relevant="false">fluphenazine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.330" epochem-id="EPOCHEM:NEW:COMPOUND:1072" name="thioridazine" comment="" chebi-id="CHEBI:9566" relevant="false">thioridazine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.331" epochem-id="EPOCHEM:NEW:COMPOUND:1073" name="trifluoperazine" comment="" chebi-id="CHEBI:45951" relevant="false">trifluoperazine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.332" epochem-id="EPOCHEM:COMPOUND:6405" name="chlorpromazine" comment="" chebi-id="CHEBI:3647" relevant="false">chlorpromazine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.333" epochem-id="EPOCHEM:NEW:COMPOUND:1074" name="triflupromazine" comment="" chebi-id="WO2007038867:818450" relevant="false">triflupromazine</ne> and the like; <ne type="ONT" id="WO2007038867.HC.class-names.81" epochem-id="EPOCHEM:NEW:CLASS:822" name="anti-inflammatory substances" comment="" chebi-id="CHEBI:35472" relevant="false">anti-inflammatory substances</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.80" epochem-id="EPOCHEM:NEW:CLASS:821" name="psychotropics" comment="" chebi-id="CHEBI:35471" relevant="false">psychotropics</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.88" epochem-id="EPOCHEM:NEW:CLASS:829" name="antimanics" comment="" chebi-id="CHEBI:35477" relevant="false">antimanics</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.82" epochem-id="EPOCHEM:NEW:CLASS:823" name="stimulants" comment="" chebi-id="WO2007038867:411173" relevant="false">stimulants</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.83" epochem-id="EPOCHEM:NEW:CLASS:824" name="decongestants" comment="" chebi-id="WO2007038867:288831" relevant="false">decongestants</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.87" epochem-id="EPOCHEM:NEW:CLASS:828" name="antianginal drugs" comment="" chebi-id="WO2007038867:40292" relevant="false">antianginal drugs</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.86" epochem-id="EPOCHEM:NEW:CLASS:827" name="vasodilators" comment="" chebi-id="WO2007038867:890445" relevant="false">vasodilators</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.84" epochem-id="EPOCHEM:NEW:CLASS:825" name="antiarrhythmics" comment="" chebi-id="WO2007038867:34921" relevant="false">antiarrhythmics</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.85" epochem-id="EPOCHEM:NEW:CLASS:826" name="vasoconstrictors" comment="" chebi-id="WO2007038867:295419" relevant="false">vasoconstrictors</ne>; migraine treatments; <ne type="ONT" id="WO2007038867.HC.class-names.89" epochem-id="EPOCHEM:NEW:CLASS:830" name="diuretics" comment="" chebi-id="CHEBI:35498" relevant="false">diuretics</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.18" epochem-id="EPOCHEM:NEW:CLASS:250" name="antispasmodic agents" comment="" chebi-id="WO2007038867:708795" relevant="false">antispasmodic agents</ne> such as salts of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.334" epochem-id="EPOCHEM:COMPOUND:4382" name="atropine" comment="" chebi-id="CHEBI:16684" relevant="false">atropine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.335" epochem-id="EPOCHEM:NEW:COMPOUND:1075" name="methantheline" comment="" chebi-id="WO2007038867:546935" relevant="false">methantheline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.336" epochem-id="EPOCHEM:NEW:COMPOUND:1076" name="papaverine" comment="" chebi-id="CHEBI:28241" relevant="false">papaverine</ne> and the like <ne type="ONT" id="WO2007038867.HC.class-names.90" epochem-id="EPOCHEM:NEW:CLASS:831" name="antiasthmatics" comment="" chebi-id="WO2007038867:421424" relevant="false">antiasthmatics</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.91" epochem-id="EPOCHEM:NEW:CLASS:832" name="anti-parkinson agents" comment="" chebi-id="WO2007038867:838297" relevant="false">anti-parkinson agents</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.92" epochem-id="EPOCHEM:NEW:CLASS:833" name="expectorants" comment="" chebi-id="WO2007038867:596364" relevant="false">expectorants</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.95" epochem-id="EPOCHEM:NEW:CLASS:835" name="cough suppressants" comment="" chebi-id="WO2007038867:24728" relevant="false">cough suppressants</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.94" epochem-id="EPOCHEM:NEW:CLASS:834" name="mucolytics" comment="" chebi-id="WO2007038867:350960" relevant="false">mucolytics</ne>; <ne type="ONT" id="WO2007038867.HC.class-names.93" epochem-id="EPOCHEM:NEW:CLASS:552" name="vitamins" comment="" chebi-id="CHEBI:33229" relevant="false">vitamins</ne>; mineral and nutritional additives.
The dosage forms of the present invention preferably further comprises a floating layer.
The floating layer can comprise at least one ingredient having a true density, which is less than density of water. Preferably, the floating layer comprise a component selected from the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.210" epochem-id="EPOCHEM:COMPOUND:734" name="methacrylic acid" comment="" chebi-id="CHEBI:25219" relevant="false">methacrylic acid</ne> copolymers (e.g. Eudragit L, Eudragit E, Eudragit S100), <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.181" epochem-id="EPOCHEM:NEW:COMPOUND:1026" name="stearyl alcohol" comment="" chebi-id="CHEBI:32154" relevant="false">stearyl alcohol</ne>, hydrogeneted vegetable oil (e.g Lubritab), <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.183" epochem-id="EPOCHEM:NEW:COMPOUND:1027" name="glyceryl monooleate" comment="" chebi-id="WO2007038867:7731" relevant="false">glyceryl monooleate</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.185" epochem-id="EPOCHEM:NEW:COMPOUND:1028" name="glyceryl monostearate" comment="" chebi-id="WO2007038867:838036" relevant="false">glyceryl monostearate</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.187" epochem-id="EPOCHEM:NEW:COMPOUND:1029" name="glyceryl behenate" comment="" chebi-id="WO2007038867:448684" relevant="false">glyceryl behenate</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.189" epochem-id="EPOCHEM:NEW:COMPOUND:1030" name="glyceryl palmitostearate" comment="" chebi-id="WO2007038867:863055" relevant="false">glyceryl palmitostearate</ne>, <ne type="ONT" id="WO2007038867.HC.class-names.19" epochem-id="EPOCHEM:NEW:CLASS:251" name="medium chain triglecerides" comment="" chebi-id="WO2007038867:947078" relevant="false">medium chain triglecerides</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.337" epochem-id="EPOCHEM:NEW:COMPOUND:441" name="lecithin" comment="" chebi-id="CHEBI:16110" relevant="false">lecithin</ne>, and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.191" epochem-id="EPOCHEM:COMPOUND:693" name="stearic acid" comment="" chebi-id="CHEBI:28842" relevant="false">stearic acid</ne>, or alternatively being made of at least one excipient having a true density higher than water, but that when compressed at low pressure such that the density of the resulting tablet is less than water, while providing high tablet hardness and integrity, such as Kollidon SR. The floating layer can be present in the dosage form in an amount of about 20 to about 80 % by weight (preferably about 30 to about 60 % by weight) based on the total weight of the dosage form.
In the dosage forms of the present invention, the <ne type="ONT" id="WO2007038867.HC.class-names.54" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or salt thereof can be present in the dosage form in an amount of about 5 to about 50 % by weight (preferably about 10 to about 35 % by weight) based on the total weight of the dosage form. The <ne type="ONT" id="WO2007038867.HC.class-names.55" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> is preferably <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.10" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>. The <ne type="ONT" id="WO2007038867.HC.class-names.162" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> can be present in the dosage form in amount of about 5 to about 70 % by weight (preferably about 10 to about 50 % by weight) based on the total weight of the dosage form. Preferably, the dosage form further comprises at least one pharmaceutical acceptable carrier. The pharmaceutical acceptable carrier can be present in the dosage form in an amount of about 30 to about 90 % by weight (preferably about 50 to about 70 % by weight) based on the total weight of the dosage form. The dosage forms of the present invention can release about 10 to about 75 % (preferably about 20 to about 60 %) of the total amount of the <ne type="ONT" id="WO2007038867.HC.class-names.163" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, into the mammal stomach.
The dosage forms of the present invention can release about 25 to about 75 % (preferably about 35 to about 65 %) of the total amount of the <ne type="ONT" id="WO2007038867.HC.class-names.164" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, into the mammal proximal intestine.
The dosage forms of the present invention can release less than about 30 % (preferably less than about 10 %) of the total amount of the <ne type="ONT" id="WO2007038867.HC.class-names.165" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, into the mammal colon. The dosage forms of the present invention are particularly useful for human. The dosage forms of the present invention are also preferably once-a-day dosage forms or twice-daily dosage forms. Preferably, the dosage forms are pH insensitive. They can have a substantially constant dissolution rate for a period of at least 1 to 8 hours when administered to the mammal. Alternatively, they can have, one hour after administration, a substantially constant dissolution rate over a period of at least 1 to 7 hours.
The dosage forms can have a diameter of about 9 mm to about 14 mm, and preferably of about 10 mm to about 12 mm. The dosage forms can have a density of about 0.7 g/mL to about 1.0 g/tnL, and preferably of about 0.7 g/mL to about 0.95 g/mL.
In accordance with a one embodiment of the present invention there is provided a once-a-day sustained-release oral dosage form comprising:
a first layer including a <ne type="ONT" id="WO2007038867.HC.class-names.166" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.11" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof; and
a second layer including a floating agent,
wherein the <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.12" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof reduces the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.167" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 1.0 to about 3.5, and enhances the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.168" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 4.0 to about 7.0. In accordance with another embodiment of the present invention there is provided a once-a-day sustained-release oral dosage form comprising: a first layer including a <ne type="ONT" id="WO2007038867.HC.class-names.169" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.13" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof; and
a second layer including a floating agent,
wherein the <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.14" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof is effective for maintaining the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.170" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 5 % by weight per hour to about 50 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.171" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when the dosage form is at a pH of about 4.0 to about
</P>
<P>7.0.
In accordance with another embodiment of the present invention there is provided a once-a-day sustained-release oral dosage form comprising:
a first layer including a <ne type="ONT" id="WO2007038867.HC.class-names.172" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.15" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof; and
a second layer including a floating agent,
wherein the <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.16" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof is effective for maintaining the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.173" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 10 % by weight per hour to about 60 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.174" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when the dosage form is at a pH of about 1.0 to about
</P>
<P>3.5.
In accordance with another embodiment of the present invention there is provided a once-a-day sustained-release oral dosage form comprising:
a first layer including a <ne type="ONT" id="WO2007038867.HC.class-names.175" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.17" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>; and
a second layer including a floating agent, wherein the dosage form releases no more than 60 % of the total amount of the <ne type="ONT" id="WO2007038867.HC.class-names.176" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> within a first hour, the remaining amount of the <ne type="ONT" id="WO2007038867.HC.class-names.177" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> being released over a period of time of about 5 to about 8 hours subsequent to the first hour. In accordance with another embodiment of the present invention there is provided a once-a-day sustained-release oral dosage form comprising:
a first layer including a <ne type="ONT" id="WO2007038867.HC.class-names.178" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.18" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>; and
a second layer including a floating agent,
wherein the <ne type="ONT" id="WO2007038867.HC.class-names.179" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in the dosage form has a dissolution rate of about 10% by weight per hour to about 60% by weight per hour when being at a pH of about 1.0 to about 3.5, and a dissolution rate of about 5% by weight per hour to about 50% by weight per hour when being at a pH of about 4.0 to about 7.0. The dosage forms of the present invention can be used in the treatment of acne, preferably when the <ne type="ONT" id="WO2007038867.HC.class-names.180" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.397" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne>. They can also be used in the treatment of infection by anthrax. When used for treating anthrax, the <ne type="ONT" id="WO2007038867.HC.class-names.181" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in the dosage form of the present invention is preferably <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.398" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.84" epochem-id="EPOCHEM:NEW:COMPOUND:1017" name="doxycycline" comment="" chebi-id="WO2007038867:253304" relevant="false">doxycycline</ne>, or a mixture thereof. Alternatively, the dosages forms of the present invention can be used for the treatment of irritable bowel syndrome. In such a case, the <ne type="ONT" id="WO2007038867.HC.class-names.182" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is preferably <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.168" epochem-id="EPOCHEM:NEW:COMPOUND:1025" name="trimebutine" comment="" chebi-id="WO2007038867:857445" relevant="false">trimebutine</ne>.
In accordance with another aspect of the present invention there is provided a kit for treating acne comprising a dosage form as defined in the present invention and instructions for using the dosage form. In accordance with another aspect of the present invention there is provided a kit for treating infection by anthrax comprising a dosage form as defined in the present invention and instructions for using the dosage form.
In accordance with another aspect of the present invention there is provided a kit for treating irritable bowel syndrome comprising a dosage form as defined in the present invention and instructions for using the dosage form.
In accordance with another aspect of the present invention there is provided a method for treating acne comprising the step of administering to a patient suffering from this disease a dosage form as defined in the present invention. The dosage form is preferably administered to a patient once-a- day. The <ne type="ONT" id="WO2007038867.HC.class-names.183" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in such a dosage form is preferably <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.399" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne>.
In accordance with another aspect of the present invention there is provided a method for treating infection by anthrax comprising the step of administering to a patient suffering from this disease a dosage form as defined in the present invention. The <ne type="ONT" id="WO2007038867.HC.class-names.184" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in such a dosage form is preferably <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.400" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> or <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.85" epochem-id="EPOCHEM:NEW:COMPOUND:1017" name="doxycycline" comment="" chebi-id="WO2007038867:253304" relevant="false">doxycycline</ne>.
In accordance with another aspect of the present invention there is provided a method for treating irritable bowel syndrome comprising the step of administering to a patient suffering from this disease a dosage form as defined in the present invention. The <ne type="ONT" id="WO2007038867.HC.class-names.185" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in such a dosage form is preferably <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.169" epochem-id="EPOCHEM:NEW:COMPOUND:1025" name="trimebutine" comment="" chebi-id="WO2007038867:857445" relevant="false">trimebutine</ne>.
In accordance with another aspect of the present invention there is provided the use of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.19" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof for controlling the dissolution rate of a <ne type="ONT" id="WO2007038867.HC.class-names.186" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in a dosage form comprising the <ne type="ONT" id="WO2007038867.HC.class-names.187" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and the <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.20" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof, wherein the <ne type="LIGAND" id="WO2007038867.HC.ligand-names.10" epochem-id="EPOCHEM:NEW:LIGAND:164" name="sorbic" comment="" chebi-id="WO2007038867:32944" relevant="false">sorbic</ne> or salt thereof acid reduces the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.188" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 1.0 to about 3.5, and enhances the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.189" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 4.0 to about 7.0.
In accordance with another aspect of the present invention there is provided the use of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.21" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof for controlling the dissolution rate of a <ne type="ONT" id="WO2007038867.HC.class-names.190" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in a dosage form comprising the <ne type="ONT" id="WO2007038867.HC.class-names.191" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and the <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.22" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof, wherein the <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.23" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof is effective for maintaining the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.192" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 5 % by weight per hour to about 50 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.193" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when the dosage form is an environment at pH of about 4.0 to about7.0.
In accordance with another aspect of the present invention there is provided the use of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.24" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof as a dissolution regulator in the preparation of a dosage form for releasing a pH-dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.194" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>.
In accordance with another aspect of the present invention there is provided the use of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.25" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof as a dissolution regulator in the preparation of a dosage form for releasing a pH-dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.195" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, for providing to the <ne type="ONT" id="WO2007038867.HC.class-names.196" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> a dissolution rate of about 5 % by weight per hour to about 50 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.197" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when the dosage form is in an environment at a pH of about 4.0 to about 7.0.
In accordance with another aspect of the present invention there is provided the use of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.26" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof as a dissolution regulator in the preparation of a dosage form for releasing a pH-dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.198" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, for providing to the dosage form a dissolution rate which is substantially pH- insensitive when pH is about 1.0 to about 7.0.
In accordance with another aspect of the present invention there is provided a method for regulating or controlling the dissolution rate of a pH- dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.199" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> comprising the step of preparing a dosage form including the <ne type="ONT" id="WO2007038867.HC.class-names.200" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.27" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof.
In accordance with another aspect of the present invention there is provided a method for regulating or controlling the dissolution rate of a pH- dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.201" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in such a manner that the <ne type="ONT" id="WO2007038867.HC.class-names.202" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> has a dissolution rate which is substantially the same when submitted to a pH of about 1.0 to about 3.5 and when submitted to a pH of about 4.0 to about 7.0, the method comprising the step of preparing a dosage form including the <ne type="ONT" id="WO2007038867.HC.class-names.203" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.28" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof.
In accordance with another aspect of the present invention there is provided a method for enhancing absorption of a <ne type="ONT" id="WO2007038867.HC.class-names.204" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at the level of proximal intestine, the method comprising the step of administering to a patient an oral dosage form including the <ne type="ONT" id="WO2007038867.HC.class-names.205" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.29" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof.
In accordance with another aspect of the present invention there is provided a method for enhancing delivery of a <ne type="ONT" id="WO2007038867.HC.class-names.206" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> to stomach and proximal intestine of a patient while minimizing delivery to distal intestine and colon of the patient, the method comprising orally administering to the patient a sustained-release oral dosage form comprised of a <ne type="ONT" id="WO2007038867.HC.class-names.207" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.30" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof, wherein <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.31" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof reduces the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.208" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> when the dosage form is within stomach of the patient at a pH of about 1.0 to about 3.5, and wherein <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.32" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> enhances the dissolution rate of the <ne type="ONT" id="WO2007038867.HC.class-names.209" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> when the <ne type="ONT" id="WO2007038867.HC.class-names.210" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is within proximal intestine of the patient at a pH of about 4.0 to about 7.0.
In accordance with another aspect of the present invention there is provided a method for enhancing delivery of a <ne type="ONT" id="WO2007038867.HC.class-names.211" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> to stomach and proximal intestine of a patient while minimizing delivery to distal intestine and colon of the patient, the method comprising orally administering to the patient an oral dosage form as defined in the present invention.
In accordance with another embodiment of the present invention there is provided an oral dosage form for treating acne. The dosage form comprises <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.401" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.56" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.218" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.234" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.249" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.33" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.263" epochem-id="EPOCHEM:COMPOUND:811" name="benzoic acid" comment="" chebi-id="CHEBI:30746" relevant="false">benzoic acid</ne> and salts thereof,
wherein the dosage form is suitable for treating acne by means of a once-a-day administration. The <ne type="ONT" id="WO2007038867.HC.class-names.57" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> is preferably <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.34" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>.
In accordance with another embodiment of the present invention there is provided an oral dosage form for treating acne. The dosage form comprises: a first layer including <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.402" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.58" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.219" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.235" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne> <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.250" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.35" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, and salts thereof,
a second layer including a floating agent, wherein the dosage form is suitable for treating acne by means of a once-a-day administration. The <ne type="ONT" id="WO2007038867.HC.class-names.59" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> is preferably <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.36" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>.
In accordance with another embodiment of the present invention there is provided a controlled-release oral dosage form for releasing a <ne type="ONT" id="WO2007038867.HC.class-names.212" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> according to a <ne type="ONT" id="WO2007038867.HC.class-names.213" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> release profile as defined in Fig. 3. In accordance with another embodiment of the present invention there is provided a controlled-release oral dosage form for releasing a <ne type="ONT" id="WO2007038867.HC.class-names.214" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, wherein the dosage form allows to the <ne type="ONT" id="WO2007038867.HC.class-names.215" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> a controlled-release permitting to the <ne type="ONT" id="WO2007038867.HC.class-names.216" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> to have a plasma concentration as defined in Fig. 1.
In accordance with another embodiment of the present invention there is provided a controlled-release oral dosage form for releasing a <ne type="ONT" id="WO2007038867.HC.class-names.217" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, the dosage form being characterized in that it permits to the <ne type="ONT" id="WO2007038867.HC.class-names.218" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> a release as defined in Fig. 3.
In accordance with another embodiment of the present invention there is provided a controlled-release oral dosage form for releasing a <ne type="ONT" id="WO2007038867.HC.class-names.219" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, the dosage being characterized in that it permits to the <ne type="ONT" id="WO2007038867.HC.class-names.220" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> to have a plasma concentration as defined in Fig. 1.
The person skilled in the art would understand that the preferred embodiments with respect to the dosage forms of the present invention can also apply to the kit, methods and uses of the present invention. It should also be understood that the dosage forms of the invention are all provided to patients in therapeutically effective amounts. BRIEF DESCRIPTION OF THE DRAWINGS
Several features and advantages of the present invention will become more readily apparent from the following drawings which represent in a non-limitative manner preferred embodiments of the invention. Fig.1 represents a comparison between plasmatic concentration curves of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.195" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>(TM) immediate release twice daily 50 mg and a 100 mg control-release dosage form according to a preferred embodiment of the present invention, in which the <ne type="ONT" id="WO2007038867.HC.class-names.221" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.403" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne>;
Fig. 2 represents a dosage form according to another preferred embodiment of the invention, wherein the dosage form has a bilayer tablet configuration;
Fig. 3 represents a <ne type="ONT" id="WO2007038867.HC.class-names.222" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> release profile, at various pH, of a bilayer dosage form according to another preferred embodiment of the present invention, wherein the <ne type="ONT" id="WO2007038867.HC.class-names.223" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.404" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne>; Fig. 4 represents a dosage form according to another preferred embodiment of the invention, wherein the dosage form has a single layer configuration;
Fig. 5 represents a <ne type="ONT" id="WO2007038867.HC.class-names.224" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> release profile, at various pH, of a single layer dosage form according to another preferred embodiment of the present invention, wherein the <ne type="ONT" id="WO2007038867.HC.class-names.225" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.170" epochem-id="EPOCHEM:NEW:COMPOUND:1025" name="trimebutine" comment="" chebi-id="WO2007038867:857445" relevant="false">trimebutine</ne>; and
Fig. 6 represents a <ne type="ONT" id="WO2007038867.HC.class-names.226" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> release profile, at various pH, of a single layer dosage form according to another preferred embodiment of the present invention, wherein the <ne type="ONT" id="WO2007038867.HC.class-names.227" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.405" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> (200 mg).
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION
The present invention will be more readily understood by referring to the following example, which represents in a non-limitative manner preferred embodiments. EXAMPLE 1
A controlled release dosage form was prepared according to following general method. The ingredients and their proportions are shown in
Table 1. The dosage form of Example 1 , a <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.406" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> tablet, is in fact a bilayer tablet as shown in Fig. 2. It comprises a release layer including <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.407" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> and a floating layer.
The <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.408" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> release layer is manufactured as follows. <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.386" epochem-id="EPOCHEM:NEW:COMPOUND:2100" name="minocycline HCI" comment="minocycline HCl" chebi-id="WO2007038867:804335" relevant="false">Minocycline HCI</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.37" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, and <ne type="CHEMICAL" id="WO2007038867.HC.substance-names.9" epochem-id="EPOCHEM:NEW:SUBSTANCE:304" name="HPMC" comment="" chebi-id="WO2007038867:625050" relevant="false">HPMC</ne> are granulated with water in a high shear granulator. The granules are then dried in a fluid bed dryer, and sized. Kollidon SR is added, and then the blend is lubricated with PRUV. The floating layer is prepared by first blending Kollidon SR and Lubritab. Silicon dioxide is incorporated, and the blend is lubricated by incorporating PRUV.
The tablet is formed onto a single punch Manesty F3 press by first introducing 270 mg of the floating layer introduced into a 12.0 mm round die (concave tooling punch). The floating layer is tamped slightly by lowering upper punch. The release layer (325mg) is introduced into the die on top of the floating layer, and a full compression cycle is performed. The thickness of the tablet is in the range 6.4-7.4 mm, with a hardness of 40-70N. The resulting tablet floats immediately upon contact with water.
Table 1 Formulation of a <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.410" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> bilayer tablet
</P>
<P>[0113]
EMI21.1
*At 6.5% humidity and 100% potency, equivalent to 100mg <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.411" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">Minocycline</ne> base ** Removed during the process
The dosage form of Example 1 , as shown in Fig. 3, shows a release profile that has a relative insensitivity to different pH treatments in the course of dissolution. In fact, it can be seen from Fig. 3 that the dosage form of Example 1 is pH-insensitive.
In Example 1 , a floating device (or floating layer) of relatively large diameter is added so as to keep the tablet for an extended period of time into a fed stomach. The floating object preferably remains physically intact (no extensive erosion with time), and penetration of water is preferably kept to a minimum. The air present in the tablet can help to keep the device floating. In the present invention, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.412" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> is preferably released from a compartment of the tablet that is separated from the floating device or layer. The floating and release layers or compartments are thus formulated into a bilayer tablet, as illustrated in Fig. 2, and which is preferably a round, biconcave tablet.
As shown in Fig. 3, close to 40 % of <ne type="ONT" id="WO2007038867.HC.class-names.228" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is released from the <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.413" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> layer within the first hour. Then, the remaining dose is released over the next 6 to 8 hours i.e. 6 to 8 hours later. This release profile is somewhat peculiar, as the formulation releases rapidly initially, followed by a somewhat linear release thereafter. This is caused by the particular nature and combination of the various ingredients.
The floating layer maintains the tablet as long as possible in the stomach. A floating tablet of large diameter increases the overall residence time of tablets in fed subject (Hou et al. Critical Reviews(TM) in Therapeutic <ne type="ONT" id="WO2007038867.HC.class-names.229" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">Drug</ne> Carrier Systems, 20(6), 461-497, 2003). Since the absorption window of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.414" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> is substantially limited to the proximal portion of the intestine, the longer the tablet is retained in the stomach, the longer it take for the tablet to reach intestinal regions of lesser absorption. A longer transit time can be used advantageously to stretch absorption time and obtained an extended plasmatic plateau.
Since the dosage form remains in the stomach for an extended period of time, thus at relatively low pH values of around 1.0 to 3.5 for a fed stomach, and then be transferred in the small intestine at a pH range of 5 to 7, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.415" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> solubility varies considerably with localization in the gastrointestinal tract. The previously discussed figures show that <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.38" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, at low pH, reduces the solubility rate of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.416" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> and that at higher pH, it enhances the solubility rate of minocyclicne. This is a considerable advantage over the prior art <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.417" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> dosage forms, which quickly release the <ne type="ONT" id="WO2007038867.HC.class-names.230" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at low pH. Moreover, in the prior art <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.418" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> dosage forms, the release is slowed down dramatically upon transfer to neutral or higher pH. In fact, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.436" epochem-id="EPOCHEM:NEW:COMPOUND:2100" name="minocycline HCI" comment="minocycline HCl" chebi-id="CHEBI:6940" relevant="false">minocycline HCI</ne> has a solubility greater than 500 mg/mL at a pH of about 1.0 and it has a solubility of about 52 mg/mL at a pH of about 6.7. In the present invention, the differential solubility of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.437" epochem-id="EPOCHEM:NEW:COMPOUND:2100" name="minocycline HCI" comment="minocycline HCl" chebi-id="CHEBI:6940" relevant="false">minocycline HCI</ne> is compensated by <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.39" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, which has a solubility profile that is the reverse of that of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.438" epochem-id="EPOCHEM:NEW:COMPOUND:2100" name="minocycline HCI" comment="minocycline HCl" chebi-id="CHEBI:6940" relevant="false">minocycline HCI</ne>. The compound used in example 1 is <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.40" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>. <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.41" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">Sorbic acid</ne> has a solubility of about 2.5 mg/mL at a pH lower than 4.8, and it has solubility of about 333 mg/mL at a pH higher than 4.8.
In the tablet of Example 1 at low pH, as the solubility of minocyline HCI is relatively higher, the solubility of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.42" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> is minimal. Under this pH condition, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.43" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> acts as a barrier to the dissolution of highly soluble <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.439" epochem-id="EPOCHEM:NEW:COMPOUND:2100" name="minocycline HCI" comment="minocycline HCl" chebi-id="CHEBI:6940" relevant="false">minocycline HCI</ne>.
At higher pH, however, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.44" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> becomes readily soluble, and generates pores into the tablet which enhances the solubilisation of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.387" epochem-id="EPOCHEM:NEW:COMPOUND:2100" name="minocycline HCI" comment="minocycline HCl" chebi-id="WO2007038867:804335" relevant="false">minocycline HCI</ne>. The lower solubility of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.440" epochem-id="EPOCHEM:NEW:COMPOUND:2100" name="minocycline HCI" comment="minocycline HCl" chebi-id="CHEBI:6940" relevant="false">minocycline HCI</ne> at higher pH is therefore compensated by the increased afflux of water within the tablet as <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.45" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> is leached away. Kollidon SR act as a long-acting agent preserving the integrity of the tablet and opposing the rapid swelling of Methocel E5 by incoming water. Methocell E5 acts as a gelifying agent which also controls the inward movement of water, and act as a slow disintegration agent. It also controls the initial burst of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.425" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne>. Kollidon SR further gives a tablet with high hardness at low compression force. That allows compression of the tablet at a relatively low density which guarantees the floatability of tablet. Other low molecular weight <ne type="ONT" id="WO2007038867.HC.class-names.31" epochem-id="EPOCHEM:NEW:CLASS:370" name="organic acids" comment="" chebi-id="WO2007038867:387662" relevant="false">organic acids</ne> with solubility properties similar to <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.46" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> and which can alternatively be used be used in the dosage form. These acids can be <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.220" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.236" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.264" epochem-id="EPOCHEM:COMPOUND:811" name="benzoic acid" comment="" chebi-id="CHEBI:30746" relevant="false">benzoic acid</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.251" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>. Other low molecular weight <ne type="ONT" id="WO2007038867.HC.class-names.32" epochem-id="EPOCHEM:NEW:CLASS:370" name="organic acids" comment="" chebi-id="WO2007038867:387662" relevant="false">organic acids</ne> such as <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.442" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.443" epochem-id="EPOCHEM:COMPOUND:157" name="tartaric acid" comment="" chebi-id="CHEBI:15674" relevant="false">tartaric acid</ne> could also be used.
Given the relatively long plasma half-life of 11 to 26 hours for <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.426" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne>, the extended residence time provided by a floating layer is found to provide a satisfactory pharmacokinetic profile, as shown in Fig. 1. Fig. 1 shows the in vivo plasmatic concentration profiles. Fig. 1 also contains the plasmatic profile for immediate release twice daily 50 mg tablet. As it can be seen from Fig. 1 and Table 2, the dosage of Example 1 is more favorable than <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.196" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>(TM).
Table 2
Comparison of bioequivalents data for <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.197" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>(TM) and the dosage form of Example 1
</P>
<P>[0123]
EMI24.1
Fig. 1 shows plasmatic concentration of <ne type="ONT" id="WO2007038867.HC.class-names.231" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in blood circulation for the once-a-day dosage form of Example 1 as opposed to the twice-a-day reference formulation <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.198" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>(TM). Table 2 provides numerical data describing and summarizing the critical information that can be extracted from the curves in Fig. 1. Of considerable importance is the comparison of the area under the curve (AUC) for the two products and the ratio of the geometric means for the AUC for the test and reference products. For example, the % ratio of the geometric means for the AUC over 24 hr is 102.64%, and is 88.52 over 48 hrs, indicating the test and reference products are bioequivalent. The tablet also indicate that the maximum concentration achieve is similar in either cases. Tmax is somewhat different, as can be expected, but that has no impact on bioavailability properties.
The person skilled in the art would thus recognize the several advantages of the dosage form of Example 1 over <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.199" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>(TM). Firstly, the dosage form of Example 1 is a once-a-day dosage form as opposed to
<ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.200" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>(TM), which has to be taken twice a day. As previously mentioned, the dosage form of Example 1 is bioequivalent to <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.201" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>(TM), i.e. a similar amount of <ne type="ONT" id="WO2007038867.HC.class-names.232" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is found into the blood circulation when the dosage form of Example 1 or <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.202" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>(TM) are taken. However, patient takes only one tablet of the dosage form of Example 1 per day instead of two tablets <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.203" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>(TM) per day. Besides being more practical, taking one tablet per day results in better patient compliance to treatment than having to take two <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.204" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>(TM) tablet per day.
The dosage form of Example 1 shows a quick unset of plasmatic concentration, almost as quick as <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.205" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>(TM), and then shows a sustained plasmatic concentration. On the other hand, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.206" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>(TM) provides a marked fluctuation in blood concentration over a 24 hr cycle. The variation in blood concentration is lessened with the dosage form of Example 1 as compared to <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.207" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>. Such a fact can be clearly seen form Fig. 1 since the dosage form of Example 1 provides essentially one peak and one valley per 24 hrs, whereas <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.208" epochem-id="EPOCHEM:NEW:COMPOUND:1032" name="Minocin" comment="" chebi-id="CHEBI:6940" relevant="false">Minocin</ne>(TM) provides two peaks and two valleys per day. Many other different dosages can be prepared in accordance with the present invention, ranging from 20 mg to 300mg.
EXAMPLE 2
A controlled release dosage form was prepared according to following general method. The ingredients and their proportions are shown in Table 3. The dosage form of Example 2, a <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.171" epochem-id="EPOCHEM:NEW:COMPOUND:1025" name="trimebutine" comment="" chebi-id="WO2007038867:857445" relevant="false">trimebutine</ne> tablet, is in fact a single layer tablet as shown in Fig. 4.
Table 3 Formulation of a <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.172" epochem-id="EPOCHEM:NEW:COMPOUND:1025" name="trimebutine" comment="" chebi-id="WO2007038867:857445" relevant="false">trimebutine</ne> single layer tablet
</P>
<P>[0131]
EMI26.1
The tablet is manufactured as follows. <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.163" epochem-id="EPOCHEM:NEW:COMPOUND:1024" name="trimebutine maleate" comment="" chebi-id="WO2007038867:235352" relevant="false">Trimebutine maleate</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.47" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.193" epochem-id="EPOCHEM:NEW:COMPOUND:1031" name="propyl gallate" comment="" chebi-id="WO2007038867:90076" relevant="false">propyl gallate</ne>, and <ne type="CHEMICAL" id="WO2007038867.HC.substance-names.10" epochem-id="EPOCHEM:NEW:SUBSTANCE:304" name="HPMC" comment="" chebi-id="WO2007038867:625050" relevant="false">HPMC</ne> are granulated with water in a high shear granulator. The granules are then dried in a fluid bed dryer, and sized. Kollidon SR is added, and then the blend is lubricated with Colloidal silicon dioxide and PRUV.
The tablet is formed onto a single punch Manesty F3 press using a 12.0 mm round die (concave tooling punch). The thickness of the tablet is in the range 6.0-6.5, with a hardness of over 9ON. The resulting tablet is not a floating tablet.
The dosage form of Example 2, as shown in Fig. 5, shows a release profile that has a relative insensitivity to different pH treatments in the course of dissolution. In fact, it can be seen from Fig. 5 that the dosage form of Example 2 is pH-insensitive.
In Example 2, the retention of the tablet for an extended period of time into a fed stomach is essentially caused by the relatively large diameter of the tablet. The tablet has been formulated to remains physically intact with limited erosion for the initial few hours.
As shown in Fig. 5, close to 40 % of <ne type="ONT" id="WO2007038867.HC.class-names.233" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is released from the tablet within the first 2 hours. Then, the remaining dose is released over the next 8 to 10 hrs. This release profile is typical of a first order release, whereas Example 1 , Fig. 3, was more typical of a zero-order release.
<ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.174" epochem-id="EPOCHEM:NEW:COMPOUND:1025" name="trimebutine" comment="" chebi-id="WO2007038867:857445" relevant="false">Trimebutine</ne> has a solubility of about 11 mg/ml at a pH of 2, while its solubility at a pH of 5.5 is 1 mg/ml. Thus, the solubility of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.175" epochem-id="EPOCHEM:NEW:COMPOUND:1025" name="trimebutine" comment="" chebi-id="WO2007038867:857445" relevant="false">trimebutine</ne> varies considerably with localization in the gastro-intestinal tract. The previously discussed figures show that the formulation incorporating <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.48" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> compensates the differential solubility of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.176" epochem-id="EPOCHEM:NEW:COMPOUND:1025" name="trimebutine" comment="" chebi-id="WO2007038867:857445" relevant="false">trimebutine</ne> as a function of pH.
EXAMPLE 3 A controlled release dosage form was prepared according to following general method. The ingredients and their proportions are shown in Table 4. The dosage form of Example 3, a 200 mg <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.427" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne> tablet, is in fact a single layer tablet as shown in Fig. 4.
Table 4 Formulation of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.428" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">Minocycline</ne> 200mg single layer tablet
</P>
<P>[0140]
EMI27.1
* considering humidity and potency, equivalent to 200mg <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.429" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">Minocycline</ne> [0001]
The tablet is manufactured as follows. <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.441" epochem-id="EPOCHEM:NEW:COMPOUND:2100" name="Minocycline HCI" comment="Minocycline HCl" chebi-id="CHEBI:6940" relevant="false">Minocycline HCI</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.49" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.194" epochem-id="EPOCHEM:NEW:COMPOUND:1031" name="propyl gallate" comment="" chebi-id="WO2007038867:90076" relevant="false">propyl gallate</ne>, and <ne type="CHEMICAL" id="WO2007038867.HC.substance-names.11" epochem-id="EPOCHEM:NEW:SUBSTANCE:304" name="HPMC" comment="" chebi-id="WO2007038867:625050" relevant="false">HPMC</ne> are granulated with water in a high shear granulator. The granules are then dried in a fluid bed dryer, and sized. Kollidon SR is added, and then the blend is lubricated with PRUV. The tablet is formed onto a single punch Manesty F3 press using a 12.0 mm round die (concave tooling punch). The thickness of the tablet is in the range 6.0-6.5, with a hardness of over 110N. The resulting tablet is not a floating tablet. The dosage form of Example 3, as shown in Fig. 6, shows a release profile that has a relative insensitivity to different pH treatments in the course of dissolution. In fact, it can be seen from Fig. 5 that the dosage form of Example 2 is pH-insensitive.
In Example 3, the retention of the tablet for an extended period of time into a fed stomach is essentially caused by the relatively large diameter of the tablet. The tablet has been formulated to remains physically intact with limited erosion for the initial few hours.
As shown in Fig. 6, close to 35 % of <ne type="ONT" id="WO2007038867.HC.class-names.234" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is released from the tablet within the first hour. Then, the remaining dose is released over the next 6 to 8 hrs. This release profile is closer to that of a first order release, whereas in Example 1 , Fig. 3, was more typical of a zero-order release.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.
</P></DIV>
<DIV><P>
CLAIMS:
</P>
<P>1. A controlled-release oral dosage form suitable for administration to a mammal, said dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.235" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.50" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof,
wherein said dosage form releases no more than 60 % of the total amount of the <ne type="ONT" id="WO2007038867.HC.class-names.236" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> within about a first hour, the remaining amount of said <ne type="ONT" id="WO2007038867.HC.class-names.237" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> being released over a period of time of about 5 to about 10 hours subsequent to the first hour.
</P>
<P>2. The dosage form of claim 1 , wherein said <ne type="ONT" id="WO2007038867.HC.class-names.238" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is a pH-dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.239" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, which is preferably substantially soluble at a first pH of about 1.0 to about 3.5 and substantially less soluble at a pH of about 4.0 to 7.0 than at said first pH.
</P>
<P>3. The dosage form of claim 1 , wherein said <ne type="ONT" id="WO2007038867.HC.class-names.240" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is selected from the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.86" epochem-id="EPOCHEM:NEW:COMPOUND:1017" name="doxycycline" comment="" chebi-id="WO2007038867:253304" relevant="false">doxycycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.89" epochem-id="EPOCHEM:COMPOUND:5332" name="tetracycline" comment="" chebi-id="CHEBI:27902" relevant="false">tetracycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.92" epochem-id="EPOCHEM:NEW:COMPOUND:1018" name="oxytetracycline" comment="" chebi-id="WO2007038867:762180" relevant="false">oxytetracycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.431" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.141" epochem-id="EPOCHEM:NEW:COMPOUND:1020" name="chlortetracycline" comment="" chebi-id="WO2007038867:557980" relevant="false">chlortetracycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.177" epochem-id="EPOCHEM:NEW:COMPOUND:1025" name="trimebutine" comment="" chebi-id="WO2007038867:857445" relevant="false">trimebutine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.159" epochem-id="EPOCHEM:NEW:COMPOUND:1022" name="demeclocycline" comment="" chebi-id="WO2007038867:666197" relevant="false">demeclocycline</ne> and salts thereof.
</P>
<P>4. The dosage form of claim 2, wherein said <ne type="ONT" id="WO2007038867.HC.class-names.241" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.161" epochem-id="EPOCHEM:NEW:COMPOUND:1023" name="minocycline hydrochloride" comment="" chebi-id="WO2007038867:965127" relevant="false">minocycline hydrochloride</ne>.
</P>
<P>5. The dosage form of claim 2, wherein said <ne type="ONT" id="WO2007038867.HC.class-names.242" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.164" epochem-id="EPOCHEM:NEW:COMPOUND:1024" name="trimebutine maleate" comment="" chebi-id="WO2007038867:235352" relevant="false">trimebutine maleate</ne>.
</P>
<P>6. The dosage form of any one of claims 1 to 5, wherein said dosage further comprises a floating layer.
</P>
<P>7. The dosage form of claim 6, wherein said floating layer comprises at least one ingredient having a true density, which is less than density of water, such ingredient being preferably selected from the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.211" epochem-id="EPOCHEM:COMPOUND:734" name="methacrylic acid" comment="" chebi-id="CHEBI:25219" relevant="false">methacrylic acid</ne> copolymers (e.g. Eudragit L, Eudragit E, Eudragit S100), <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.182" epochem-id="EPOCHEM:NEW:COMPOUND:1026" name="stearyl alcohol" comment="" chebi-id="CHEBI:32154" relevant="false">stearyl alcohol</ne>, hydrogeneted vegetable oil (e.g. Lubritab), <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.184" epochem-id="EPOCHEM:NEW:COMPOUND:1027" name="glyceryl monooleate" comment="" chebi-id="WO2007038867:7731" relevant="false">glyceryl monooleate</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.186" epochem-id="EPOCHEM:NEW:COMPOUND:1028" name="glyceryl monostearate" comment="" chebi-id="WO2007038867:838036" relevant="false">glyceryl monostearate</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.188" epochem-id="EPOCHEM:NEW:COMPOUND:1029" name="glyceryl behenate" comment="" chebi-id="WO2007038867:448684" relevant="false">glyceryl behenate</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.190" epochem-id="EPOCHEM:NEW:COMPOUND:1030" name="glyceryl palmitostearate" comment="" chebi-id="WO2007038867:863055" relevant="false">glyceryl palmitostearate</ne>, <ne id="WO2007038867.HC.class-names.1" epochem-id="EPOCHEM:NEW:CLASS:234" name="medium chain triglycerides" comment="" chebi-id="WO2007038867:153499" relevant="false" type="CLASS">medium chain triglycerides</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.338" epochem-id="EPOCHEM:NEW:COMPOUND:441" name="lecithin" comment="" chebi-id="CHEBI:16110" relevant="false">lecithin</ne>, and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.192" epochem-id="EPOCHEM:COMPOUND:693" name="stearic acid" comment="" chebi-id="CHEBI:28842" relevant="false">stearic acid</ne>, or alternatively being made of at least one excipient having a true density higher than water, but that when compressed at low pressure such that the density of the resulting tablet is less than water, while providing high tablet hardness and integrity, such as Kollidon SR.
</P>
<P>8. The dosage form of claim 6, wherein said floating layer comprises Kollidon SR and Lubritab.
</P>
<P>9. The dosage form of any one of claims 1 to 8, wherein said <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.51" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof is present in said dosage form in an amount of about 5 to about 50 % by weight based on the total weight of said dosage form.
</P>
<P>10. The dosage form of any one of claims 1 to 8, wherein said <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.52" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof is present in said dosage form in an amount of about 10 to about 35 % by weight based on the total weight of said dosage form.
</P>
<P>11. The dosage form of any one of claims 1 to 10, wherein said <ne type="ONT" id="WO2007038867.HC.class-names.243" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is present in said dosage form in amount of about 5 to about 70 % by weight based on the total weight of said dosage form.
</P>
<P>12. The dosage form of any one of claims 1 to 10, wherein said <ne type="ONT" id="WO2007038867.HC.class-names.244" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is present in said dosage form in an amount of about 10 to about 50 % by weight based on the total weight of said dosage form.
</P>
<P>13. The dosage form of any one of claims 1 to 12, wherein said dosage form further comprises at least one pharmaceutical acceptable carrier.
</P>
<P>14. The dosage form of claim 13, wherein said pharmaceutical acceptable carrier is present in said dosage form in an amount of about 30 to about 90 % by weight based on the total weight of said dosage form.
</P>
<P>15. The dosage form of claim 13, wherein said pharmaceutical acceptable carrier is present in said dosage form in an amount of about 50 to about 70 % by weight based on the total weight of said dosage form.
</P>
<P>16. The dosage form of any one of claims 6 to 8, wherein said floating layer is present in said dosage form in an amount of about 20 to about 80 % by weight based on the total weight of said dosage form.
</P>
<P>17. The dosage form of any one of claims 6 to 8, wherein said floating layer is present in said dosage form in an amount of about 30 to about 60 % by weight based on the total weight of said dosage form.
</P>
<P>18. The dosage form of any one of claims 1 to 17, wherein said dosage form releases about 10 to about 75 % of the total amount of said <ne type="ONT" id="WO2007038867.HC.class-names.245" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, into the mammal stomach.
</P>
<P>19. The dosage form of any one of claims 1 to 17, wherein said dosage form releases about 20 to about 60 % of the total amount of said <ne type="ONT" id="WO2007038867.HC.class-names.246" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, into the mammal stomach.
</P>
<P>20. The dosage form of any one of claims 1 to 17, wherein said dosage form releases about 25 to about 75 % of the total amount of said <ne type="ONT" id="WO2007038867.HC.class-names.247" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, into the mammal proximal intestine.
</P>
<P>21. The dosage form of any one of claims 1 to 17, wherein said dosage form releases about 35 to about 65 % of the total amount of said <ne type="ONT" id="WO2007038867.HC.class-names.248" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, into the mammal proximal intestine.
</P>
<P>22. The dosage form of any one of claims 1 to 17, wherein said dosage form releases less than about 30 % of the total amount of said <ne type="ONT" id="WO2007038867.HC.class-names.249" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, into the mammal colon.
</P>
<P>23. The dosage form of any one of claims 1 to 17, wherein said dosage form releases less than about 10 % of the total amount of said <ne type="ONT" id="WO2007038867.HC.class-names.250" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, into the mammal colon.
</P>
<P>24. The dosage form of any one of claims 1 to 23, wherein said mammal is a human.
</P>
<P>25. The dosage form of any one of claims 1 to 24, wherein said dosage form is a once-a-day dosage form or a twice-a-day dosage form.
</P>
<P>26. The dosage form of any one of claims 1 to 25, wherein said dosage form is pH insensitive.
</P>
<P>27. The dosage form of any one of claims 1 to 25, wherein said dosage form has a substantially constant dissolution rate for a period of at least 1 to 10 hours when administered to said mammal.
</P>
<P>28. The dosage form of any one of claims 1 to 25, wherein said dosage form has, one hour after administration, a substantially constant dissolution rate over a period of at least 1 to 7 hours.
</P>
<P>29. The dosage form of any one of claims 1 to 28, wherein said dosage form is a tablet having a diameter of about 9 mm to about 14 mm.
</P>
<P>30. The dosage form of any one of claims 1 to 28, wherein said dosage form is a tablet having a diameter of about 10 mm to about 12 mm.
</P>
<P>31. The dosage form of any one of claims 1 to 30, wherein said dosage form has a density of about 0.7 g/mL to about 1.0 g/mL.
</P>
<P>32. The dosage form of any one of claims 1 to 30, wherein said dosage form has a density of about 0.7 g/mL to about 0.95 g/mL.
</P>
<P>33. A controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.251" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.53" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof,
wherein said <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.54" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> reduces the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.252" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 1.0 to about 3.5, and enhances the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.253" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 4.0 to about 7.0.
</P>
<P>34. A controlled-release oral dosage form comprising: a <ne type="ONT" id="WO2007038867.HC.class-names.254" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.60" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or a salt thereof, said <ne type="ONT" id="WO2007038867.HC.class-names.61" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> having a solubility lower than 20 mg/mL (preferably lower than 10 mg/mL, and more preferably lower than 3.0 mg/mL) at a pH below 5.0 and a solubility of at least 100 mg/mL (preferably at least 200 mg/mL and more preferably at least 300 mg/mL) at a pH higher than 5.0,
wherein said <ne type="ONT" id="WO2007038867.HC.class-names.62" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or salt thereof is effective for reducing the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.255" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 1.0 to about 3.5, and enhancing the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.256" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 4.0 to about 7.0.
</P>
<P>35. A controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.257" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.63" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or a salt thereof, said <ne type="ONT" id="WO2007038867.HC.class-names.64" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> having a solubility lower than 20 mg/mL (preferably lower than 10 mg/mL, and more preferably lower than 3.0 mg/mL) at a pH below 5.0 and a solubility of at least 100 mg/mL (preferably at least 200 mg/mL and more preferably at least 300 mg/mL) at a pH higher than 5.0,
wherein said <ne type="ONT" id="WO2007038867.HC.class-names.65" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or salt thereof is effective for maintaining the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.258" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 5 % by weight per hour to about 50 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.259" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when said dosage form is at a pH of about 4.0 to about 7.0.
</P>
<P>36. A controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.260" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.66" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or a salt thereof, said <ne type="ONT" id="WO2007038867.HC.class-names.67" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> having a solubility lower than 20 mg/mL (preferably lower than 10 mg/mL, and more preferably lower than 3.0 mg/mL) at a pH below 5.0 and a solubility of at least 100 mg/mL (preferably at least 200 mg/mL and more preferably at least 300 mg/mL) at a pH higher than 5.0,
wherein said <ne type="ONT" id="WO2007038867.HC.class-names.68" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or salt thereof is effective for maintaining the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.261" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 10 % by weight per hour to about 60 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.262" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when said dosage form is at a pH of about 1.0 to about 3.5
</P>
<P>37. A controlled-release oral dosage form suitable for human administration comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.263" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.69" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or a salt thereof, said <ne type="ONT" id="WO2007038867.HC.class-names.70" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> having a solubility lower than 20 mg/mL (preferably lower than 10 mg/mL, and more preferably lower than 3.0 mg/mL) at a pH below 5.0 and a solubility of at least 100 mg/mL (preferably at least 200 mg/mL and more preferably at least 300 mg/mL) at a pH higher than 5.0,
wherein said dosage form releases no more than 60 % of the total amount of the <ne type="ONT" id="WO2007038867.HC.class-names.264" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> within a first hour, the remaining amount of said <ne type="ONT" id="WO2007038867.HC.class-names.265" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> being released over a period of time of about 5 to about 10 hours subsequent to the first hour.
</P>
<P>38. A controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.266" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.71" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.221" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.237" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.252" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.55" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.265" epochem-id="EPOCHEM:COMPOUND:811" name="benzoic acid" comment="" chebi-id="CHEBI:30746" relevant="false">benzoic acid</ne> and salts thereof,
wherein said <ne type="ONT" id="WO2007038867.HC.class-names.72" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or salt thereof is effective for maintaining the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.267" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 5 % by weight per hour to about 50 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.268" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when said dosage form is at a pH of about 4.0 to about 7.0.
</P>
<P>39. A controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.269" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.73" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.222" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.238" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.253" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.56" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.266" epochem-id="EPOCHEM:COMPOUND:811" name="benzoic acid" comment="" chebi-id="CHEBI:30746" relevant="false">benzoic acid</ne> and salts thereof, wherein said <ne type="ONT" id="WO2007038867.HC.class-names.74" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or salt thereof is effective for maintaining the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.270" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 10 % by weight per hour to about 60 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.271" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when said dosage form is at a pH of about 1.0 to about 3.5.
</P>
<P>40. A controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.272" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, and an <ne type="ONT" id="WO2007038867.HC.class-names.75" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.223" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.239" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.254" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.57" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.267" epochem-id="EPOCHEM:COMPOUND:811" name="benzoic acid" comment="" chebi-id="CHEBI:30746" relevant="false">benzoic acid</ne> and salts thereof,
wherein said dosage form releases no more than 60 % of the total amount of the <ne type="ONT" id="WO2007038867.HC.class-names.273" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> within a first hour, the remaining amount of said <ne type="ONT" id="WO2007038867.HC.class-names.274" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> being released over a period of time of about 5 to about 10 hours subsequent to the first hour.
</P>
<P>41. A controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.275" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.76" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.224" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.240" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.255" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.58" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.268" epochem-id="EPOCHEM:COMPOUND:811" name="benzoic acid" comment="" chebi-id="CHEBI:30746" relevant="false">benzoic acid</ne> and salts thereof,
wherein said <ne type="ONT" id="WO2007038867.HC.class-names.77" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> or salt thereof reduces the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.276" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 1.0 to about 3.5, and enhances the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.277" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 4.0 to about 7.0.
</P>
<P>42. A controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.278" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.78" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.225" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.241" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.256" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.59" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.269" epochem-id="EPOCHEM:COMPOUND:811" name="benzoic acid" comment="" chebi-id="CHEBI:30746" relevant="false">benzoic acid</ne> and salts thereof,
wherein said <ne type="ONT" id="WO2007038867.HC.class-names.279" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in said dosage form has a dissolution rate of about 10% by weight per hour to about 60% by weight per hour when being at a pH of about 1.0 to about 3.5, and a dissolution rate of about 5% by weight per hour to about 50% by weight per hour when being at a pH of about 4.0 to about 7.0.
</P>
<P>43. A controlled-release oral dosage form comprising:
a <ne type="ONT" id="WO2007038867.HC.class-names.280" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and an <ne type="ONT" id="WO2007038867.HC.class-names.79" epochem-id="EPOCHEM:NEW:CLASS:117" name="organic acid" comment="" chebi-id="WO2007038867:155788" relevant="false">organic acid</ne> selected form the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.226" epochem-id="EPOCHEM:COMPOUND:306" name="fumaric acid" comment="" chebi-id="CHEBI:18012" relevant="false">fumaric acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.242" epochem-id="EPOCHEM:COMPOUND:423" name="adipic acid" comment="" chebi-id="CHEBI:30832" relevant="false">adipic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.257" epochem-id="EPOCHEM:COMPOUND:1007" name="glutamic acid" comment="" chebi-id="CHEBI:18237" relevant="false">glutamic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.60" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.270" epochem-id="EPOCHEM:COMPOUND:811" name="benzoic acid" comment="" chebi-id="CHEBI:30746" relevant="false">benzoic acid</ne> and salts thereof,
wherein said <ne type="ONT" id="WO2007038867.HC.class-names.281" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in said dosage form has a dissolution rate which is substantially the same when submitted to a pH of about 1.0 to about 3.5 and when submitted to a pH of about 4.0 to about 7.0.
</P>
<P>44. The dosage form of any one of claims 33 to 43, wherein said dosage form further comprises a floating layer.
</P>
<P>45. A once-a-day sustained-release oral dosage form comprising:
a first layer including a <ne type="ONT" id="WO2007038867.HC.class-names.282" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.61" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof; and
a second layer including a floating agent,
wherein said <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.62" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof reduces the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.283" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 1.0 to about 3.5, and enhances the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.284" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 4.0 to about 7.0.
</P>
<P>46. A once-a-day sustained-release oral dosage form comprising:
a first layer including a <ne type="ONT" id="WO2007038867.HC.class-names.285" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.63" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof; and
a second layer including a floating agent,
wherein said <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.64" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof is effective for maintaining the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.286" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 5 % by weight per hour to about 50 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.287" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when said dosage form is at a pH of about 4.0 to about 7.0.
</P>
<P>47. A once-a-day sustained-release oral dosage form comprising:
a first layer including a <ne type="ONT" id="WO2007038867.HC.class-names.288" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.65" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof; and
a second layer including a floating agent,
wherein said <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.66" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof is effective for maintaining the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.289" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 10 % by weight per hour to about 60 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.290" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when said dosage form is at a pH of about 1.0 to about 3.5.
</P>
<P>48. A once-a-day sustained-release oral dosage form suitable for human administration comprising:
a first layer including a <ne type="ONT" id="WO2007038867.HC.class-names.291" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.67" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>; and
a second layer including a floating agent,
wherein said dosage form releases no more than 60 % of the total amount of the <ne type="ONT" id="WO2007038867.HC.class-names.292" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> within a first hour, the remaining amount of said <ne type="ONT" id="WO2007038867.HC.class-names.293" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> being released over a period of time of about 5 to about 10 hours subsequent to the first hour.
</P>
<P>49. A once-a-day sustained-release oral dosage form suitable for human administration comprising:
a first layer including a <ne type="ONT" id="WO2007038867.HC.class-names.294" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.68" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne>; and
a second layer including a floating agent,
wherein said <ne type="ONT" id="WO2007038867.HC.class-names.295" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in said dosage form has a dissolution rate of about 10% by weight per hour to about 60% by weight per hour when being at a pH of about 1.0 to about 3.5, and a dissolution rate of about 5% by weight per hour to about 30% by weight per hour when being at a pH of about 4.0 to about 7.0.
</P>
<P>50. The dosage form of any one of claims 33 to 49, wherein said <ne type="ONT" id="WO2007038867.HC.class-names.296" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is selected from the group consisting of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.87" epochem-id="EPOCHEM:NEW:COMPOUND:1017" name="doxycycline" comment="" chebi-id="WO2007038867:253304" relevant="false">doxycycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.90" epochem-id="EPOCHEM:COMPOUND:5332" name="tetracycline" comment="" chebi-id="CHEBI:27902" relevant="false">tetracycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.93" epochem-id="EPOCHEM:NEW:COMPOUND:1018" name="oxytetracycline" comment="" chebi-id="WO2007038867:762180" relevant="false">oxytetracycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.433" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.142" epochem-id="EPOCHEM:NEW:COMPOUND:1020" name="chlortetracycline" comment="" chebi-id="WO2007038867:557980" relevant="false">chlortetracycline</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.179" epochem-id="EPOCHEM:NEW:COMPOUND:1025" name="trimebutine" comment="" chebi-id="WO2007038867:857445" relevant="false">trimebutine</ne>, <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.160" epochem-id="EPOCHEM:NEW:COMPOUND:1022" name="demeclocycline" comment="" chebi-id="WO2007038867:666197" relevant="false">demeclocycline</ne> and salts thereof.
</P>
<P>51. The dosage form of claim 50, wherein said <ne type="ONT" id="WO2007038867.HC.class-names.297" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.162" epochem-id="EPOCHEM:NEW:COMPOUND:1023" name="minocycline hydrochloride" comment="" chebi-id="CHEBI:6940" relevant="false">minocycline hydrochloride</ne>.
</P>
<P>52. The dosage form of claim 50, wherein said <ne type="ONT" id="WO2007038867.HC.class-names.298" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.165" epochem-id="EPOCHEM:NEW:COMPOUND:1024" name="trimebutine maleate" comment="" chebi-id="WO2007038867:235352" relevant="true">trimebutine maleate</ne>.
</P>
<P>53. A controlled-release oral dosage form for releasing a <ne type="ONT" id="WO2007038867.HC.class-names.299" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> according to a <ne type="ONT" id="WO2007038867.HC.class-names.300" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> release profile as defined in Fig. 3, Fig. 5 or Fig. 6.
</P>
<P>54. A controlled-release oral dosage form for releasing a <ne type="ONT" id="WO2007038867.HC.class-names.301" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, wherein said dosage form allows to said <ne type="ONT" id="WO2007038867.HC.class-names.302" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> a controlled-release permitting to said <ne type="ONT" id="WO2007038867.HC.class-names.303" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> to have a plasma concentration as defined in Fig. 1.
</P>
<P>55. A controlled-release oral dosage form for releasing a <ne type="ONT" id="WO2007038867.HC.class-names.304" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, said dosage form being characterized in that it permits to said <ne type="ONT" id="WO2007038867.HC.class-names.305" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> a release as defined in Fig. 3, Fig. 5 or Fig. 6.
</P>
<P>56. A controlled-release oral dosage form for releasing a <ne type="ONT" id="WO2007038867.HC.class-names.306" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, said dosage being characterized in that it permits to said <ne type="ONT" id="WO2007038867.HC.class-names.307" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> to have a plasma concentration as defined in Fig. 1.
</P>
<P>57. Use of a dosage form as defined in any one of claims 1 to 56, for treating acne.
</P>
<P>58. Use of a dosage form as defined in any one of claims 1 to 56, for treating infection by anthrax.
</P>
<P>59. Use of a dosage form as defined in any one of claims 1 to 56, for treating irritable bowel syndrome.
</P>
<P>60. A kit for treating acne comprising a dosage form as defined in any one of claims 1 to 56 and instructions for using the dosage form.
</P>
<P>61. A kit for treating infection by anthrax comprising a dosage form as defined in any one of claims 1 to 56 and instructions for using the dosage form.
</P>
<P>62. A kit for treating irritable bowel syndrome comprising a dosage form as defined in any one of claims 1 to 56 and instructions for using the dosage form.
</P>
<P>63. A method for treating acne comprising the step of administering to a patient suffering from this disease a dosage form as defined in any one of claims 1 to 56.
</P>
<P>64. The method of claim 63, wherein said dosage form is administered to a patient once-a-day.
</P>
<P>65. A method for treating infection by anthrax comprising the step of administering to a patient suffering from this disease a dosage form as defined in any one of claims 1 to 56.
</P>
<P>66. A method for treating irritable bowel syndrome comprising the step of administering to a patient suffering from this disease a dosage form as defined in any one of claims 1 to 56.
</P>
<P>67. Use of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.69" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof for controlling the dissolution rate of a <ne type="ONT" id="WO2007038867.HC.class-names.308" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in a dosage form comprising said <ne type="ONT" id="WO2007038867.HC.class-names.309" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and said <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.70" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof, wherein said <ne type="LIGAND" id="WO2007038867.HC.ligand-names.11" epochem-id="EPOCHEM:NEW:LIGAND:164" name="sorbic" comment="" chebi-id="WO2007038867:32944" relevant="false">sorbic</ne> or salt thereof acid reduces the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.310" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 1.0 to about 3.5, and enhances the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.311" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a pH of about 4.0 to about 7.0.
</P>
<P>68. Use of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.71" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof for controlling the dissolution rate of a <ne type="ONT" id="WO2007038867.HC.class-names.312" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in a dosage form comprising said <ne type="ONT" id="WO2007038867.HC.class-names.313" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and said <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.72" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof, wherein said <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.73" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof is effective for maintaining the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.314" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at a value of about 5 % by weight per hour to about 30 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.315" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when said dosage form is an environment at pH of about 4.0 to about 7.0.
</P>
<P>69. Use of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.74" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof as a dissolution regulator in the preparation of a dosage form for releasing a pH-dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.316" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>.
</P>
<P>70. Use of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.75" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof as a dissolution regulator in the preparation of a dosage form for releasing a pH-dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.317" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, for providing to said <ne type="ONT" id="WO2007038867.HC.class-names.318" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> a dissolution rate of about 5 % by weight per hour to about 30 % by weight per hour, based on the total weight of the <ne type="ONT" id="WO2007038867.HC.class-names.319" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> included in the dosage form, when said dosage form is in an environment at a pH of about 4.0 to about 7.0.
</P>
<P>71. Use of <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.76" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof as a dissolution regulator in the preparation of a dosage form for releasing a pH-dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.320" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne>, for providing to said dosage form a dissolution rate which is substantially pH- insensitive when pH is about 1.0 to about 7.0.
</P>
<P>72. A method for regulating or controlling the dissolution rate of a pH- dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.321" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> comprising the step of preparing a dosage form including said <ne type="ONT" id="WO2007038867.HC.class-names.322" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.77" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof.
</P>
<P>73. A method for regulating or controlling the dissolution rate of a pH- dependent solubility <ne type="ONT" id="WO2007038867.HC.class-names.323" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> in such a manner that said <ne type="ONT" id="WO2007038867.HC.class-names.324" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> has a dissolution rate which is substantially the same when submitted to a pH of about 1.0 to about 3.5 and when submitted to a pH of about 4.0 to about 7.0, said method comprising the step of preparing a dosage form including said <ne type="ONT" id="WO2007038867.HC.class-names.325" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.78" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof.
</P>
<P>74. A method for enhancing absorption of a <ne type="ONT" id="WO2007038867.HC.class-names.326" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> at the level of proximal intestine, said method comprising the step of administering to a patient an oral dosage form including said <ne type="ONT" id="WO2007038867.HC.class-names.327" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.79" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or a salt thereof.
</P>
<P>75. The method of any one of claim 72 to 74, wherein said <ne type="ONT" id="WO2007038867.HC.class-names.328" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.435" epochem-id="EPOCHEM:NEW:COMPOUND:2099" name="minocycline" comment="" chebi-id="WO2007038867:157024" relevant="false">minocycline</ne>.
</P>
<P>76. A method for enhancing delivery of a <ne type="ONT" id="WO2007038867.HC.class-names.329" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> to stomach and proximal intestine of a patient while minimizing delivery to distal intestine and colon of said patient, the method comprising orally administering to the patient a sustained-release oral dosage form comprised of a <ne type="ONT" id="WO2007038867.HC.class-names.330" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> and <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.80" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof, wherein <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.81" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> or salt thereof reduces the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.331" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> when said dosage form is within stomach of said patient at a pH of about 1.0 to about 3.5, and wherein <ne type="CHEMICAL" id="WO2007038867.HC.chemical-names.82" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="true">sorbic acid</ne> enhances the dissolution rate of said <ne type="ONT" id="WO2007038867.HC.class-names.332" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> when the <ne type="ONT" id="WO2007038867.HC.class-names.333" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> is within proximal intestine of said patient at a pH of about 4.0 to about 7.0.
</P>
<P>77. A method for enhancing delivery of a <ne type="ONT" id="WO2007038867.HC.class-names.334" epochem-id="EPOCHEM:NEW:CLASS:1178" name="drug" comment="" chebi-id="CHEBI:23888" relevant="false">drug</ne> to stomach and proximal intestine of a patient while minimizing delivery to distal intestine and colon of said patient, the method comprising orally administering to the patient an oral dosage form as defined in any one of claims 1 to 54.
</P></DIV>
</BODY>
</PAPER>
